Document:

<PAGE>

                                                                   Exhibit 10.28

                           LOAN AND SECURITY AGREEMENT

     THIS LOAN AND SECURITY AGREEMENT (this "AGREEMENT") dated as of the
Effective Date between, on the one hand, SILICON VALLEY BANK, a California
corporation ("BANK"), and, on the other hand, ENDOCARE, INC., a Delaware
corporation ("ENDOCARE"), and TIMM MEDICAL TECHNOLOGIES, INC., a Delaware
corporation ("TIMM") (individually and collectively, and jointly and severally,
"BORROWER"), provides the terms and conditions on which Bank shall lend to
Borrower and Borrower shall repay Bank. The parties agree as follows:

     1 ACCOUNTING AND OTHER TERMS

     Accounting terms not defined in this Agreement shall be construed following
GAAP. Calculations and determinations must be made following GAAP. Capitalized
terms not otherwise defined in this Agreement shall have the meanings set forth
in Section 13. All other terms contained in this Agreement, unless otherwise
indicated, shall have the meaning provided by the Code to the extent such terms
are defined therein.

     1A. PHASE I AND PHASE II

     As used herein, the term "PHASE I" means: (a) the period commencing on the
Effective Date and ending on the day immediately preceding (if ever) the first
date after the Effective Date on which Bank receives the most recent monthly
financial statements (or most recent Compliance Certificate) under Section
6.2(a) (each such date, a "Quick Ratio Determination Date") indicating that
Borrower's Quick Ratio is less than 1.00 TO 1.00 (the "QUICK RATIO THRESHHOLD");
and (b) with respect to any Phase I Reset Date, the period commencing on such
Phase I Reset Date and ending on the day immediately preceding (if ever) the
first Quick Ratio Determination Date after such Phase I Reset Date that
Borrower's Quick Ratio is less than the Quick Ratio Threshhold.

     As used herein, the term "PHASE II" means: (a) the period commencing on the
first Quick Ratio Determination Date (if ever) after the Effective Date that
Borrower's Quick Ratio is less than the Quick Ratio Threshhold (the "INITIAL
PHASE II TRIGGER DATE") and ending on the first Quick Ratio Determination Date
(if ever) following 3 consecutive months after the Initial Phase II Trigger Date
during which Borrower's Quick Ratio is at all times not less than the Quick
Ratio Threshhold (such first Quick Ratio Determination Date, the "INITIAL PHASE
I RESET DATE"); and (b) with respect to any Phase I Reset Date, the period
commencing on the first Quick Ratio Determination Date (if ever) after such
Phase I Reset Date that Borrower's Quick Ratio is again less than the Quick
Ratio Threshhold (such first Quick Ratio Determination Date, a "SUBSEQUENT PHASE
II TRIGGER DATE") and ending on the first Quick Ratio Determination Date (if
ever) following 3 consecutive months after such Subsequent Phase II Trigger Date
during which Borrower's Quick Ratio is at all times not less than the Quick
Ratio Threshhold (such first Quick Ratio Determination Date, a "SUBSEQUENT PHASE
I RESET DATE").

     As used herein, the term "PHASE I RESET DATE" means, individually and
collectively, the Initial Phase I Reset Date and any Subsequent Phase I Reset
Date.

     As used herein, the term "PHASE II TRIGGER DATE" means, individually and
collectively, the Initial Phase II Trigger Date and any Subsequent Phase II
Trigger Date.

     2 LOAN AND TERMS OF PAYMENT

     2.1 PROMISE TO PAY. Borrower hereby unconditionally promises to pay Bank
the outstanding principal amount of all Credit Extensions, and all accrued but
unpaid interest thereon, as and when due in accordance with this Agreement.

     2.1.1 REVOLVING ADVANCES.

          (a) Availability. Subject to the terms and conditions of this
Agreement and to deduction of Reserves, Bank will make Advances to Borrower up
to an amount ("NET BORROWING AVAILABILITY") not to exceed the lesser of: (a) the
Maximum Revolver Amount; or (b) amounts available under the Borrowing Base;
provided,

                                      -1-

<PAGE>

however, that Bank shall have no obligation to make, or permit to remain
outstanding, Advances based on Borrower's Eligible Inventory ("INVENTORY
ADVANCES") if and to the extent the Inventory Advances exceed, or would exceed,
50% of the aggregate outstanding amount of Advances based on Borrower's Eligible
Accounts. Advances and other Credit Extensions will be made to each Borrower
based on the Eligible Accounts and Eligible Inventory of such Borrower, subject
to the Maximum Revolver Amount for all Advances and other Credit Extensions to
all Borrowers combined. Advances borrowed pursuant to this Section may be repaid
and, subject to the terms and conditions hereof, reborrowed during the term of
this Agreement.

          (b) [intentionally omitted]

          (c) Termination; Repayment. The Revolving Line terminates on the
Maturity Date, when the principal amount of all Advances, the unpaid interest
thereon, and all other Obligations shall be immediately due and payable.

     2.1.2 [intentionally omitted].

     2.1.3 [intentionally omitted]

     2.1.4 [intentionally omitted]

     2.2 OVERADVANCES. If at any time or for any reason the total of all
outstanding Advances and all other monetary Obligations exceeds Net Borrowing
Availability (an "OVERADVANCE"), Borrower shall immediately pay the amount of
the excess to Bank, without notice or demand. Without limiting Borrower's
obligation to repay to Bank the amount of any Overadvance, Borrower agrees to
pay Bank interest on the outstanding amount of any Overadvance, on demand, at
the Default Rate.

     2.3 PAYMENT OF INTEREST ON THE CREDIT EXTENSIONS.

          (a) Interest Rate; Advances. Subject to Section 2.3(b), the amounts
outstanding under the Revolving Line shall accrue interest at a per annum rate
equal to the Loan Margin above the Prime Rate, which interest shall be payable
monthly. As used herein, the term "LOAN MARGIN" means, as of any date of
determination: (a) at all times during the period that Phase I is in effect,
1.00 percentage points; and (b) at all times during the period that Phase II is
in effect, 1.50 percentage points.

          (b) Default Rate. Immediately upon the occurrence and during the
continuance of an Event of Default, Obligations shall bear interest at a rate
per annum which is five percentage points above the rate effective immediately
before such Event of Default (the "DEFAULT RATE"). Payment or acceptance of the
increased interest rate provided in this Section 2.3(b) is not a permitted
alternative to timely payment and shall not constitute a waiver of any Event of
Default or otherwise prejudice or limit any rights or remedies of Bank.

          (c) Adjustment to Interest Rate. Changes to the interest rate of any
Credit Extension based on changes to the Prime Rate shall be effective on the
effective date of any change to the Prime Rate and to the extent of any such
change.

          (d) 360-Day Year. Interest shall be computed on the basis of a 360-day
year for the actual number of days elapsed.

          (e) Debit of Accounts. Bank may debit any of Borrower's deposit
accounts, including the Designated Deposit Account, for principal and interest
payments or any other amounts Borrower owes Bank when due. These debits shall
not constitute a set-off.

          (f) [intentionally omitted]

          (g) Payment; Interest Computation; Float Charge. Interest is payable
monthly on the last calendar day of each month. In computing interest on the
Obligations, all Payments received after 12:00 p.m. Pacific time on any day
shall be deemed received on the next Business Day. In addition, at all times
while Phase II (if ever) is in effect, Bank shall be entitled to charge Borrower
a "float" charge in an amount equal to two (2)

                                      -2-

<PAGE>

Business Days interest, at the interest rate applicable to the Advances, on all
Payments received by Bank (except for Payments made directly by Borrower to Bank
from Borrower's unrestricted cash on deposit in any deposit account or
securities account of Borrower). Said float charge is not included in interest
for purposes of computing Minimum Monthly Interest (if any) under this
Agreement. The float charge for each month shall be payable on the last day of
the month. Bank shall not, however, be required to credit Borrower's account for
the amount of any item of payment which is unsatisfactory to Bank in its good
faith business judgment, and Bank may charge Borrower's Designated Deposit
Account for the amount of any item of payment which is returned to Bank unpaid.

     2.4 FEES. Borrower shall pay to Bank:

          (a) Commitment Fee. A fully earned, non-refundable commitment fee of
$40,000, on the Effective Date.

          (b) [intentionally omitted]

          (c) Termination Fee. The termination fee set forth in, and subject to
the terms of, Section 4.1 hereof.

          (d) Unused Revolving Line Facility Fee. A fee (the "UNUSED REVOLVING
LINE FACILITY FEE"), which fee shall be paid monthly, in arrears on the last
Business Day of each month with respect to such month, on a calendar year basis,
in an amount equal to one-half of one percent (0.50%) per annum multiplied by
the amount by which the Maximum Revolver Amount exceeds the average daily
principal balance of the outstanding Advances during the immediately preceding
month (or part thereof). Borrower shall not be entitled to any credit, rebate or
repayment of any Unused Revolving Line Facility Fee previously earned by Bank
pursuant to this Section notwithstanding any termination of this Agreement, or
suspension or termination of Bank's obligation to make loans and advances
hereunder.

          (e) Collateral Monitoring Fee. While Phase II (if ever) is in effect,
a monthly collateral monitoring fee of $2,000, payable in arrears on the last
day of each month (prorated for any partial month at the beginning and upon
termination of the Phase II period).

          (f) Bank Expenses. All Bank Expenses (including reasonable attorneys'
fees and expenses) incurred through and after the Effective Date, when due.

     3 CONDITIONS OF LOANS

     3.1 CONDITIONS PRECEDENT TO INITIAL ADVANCE. Bank's obligation to make the
initial Advance is subject to the condition precedent that Bank shall have
received, in form and substance satisfactory to Bank, such documents, and
evidence of completion of such other matters, as Bank may reasonably deem
necessary or appropriate, including, without limitation:

          (a) Borrower shall have delivered duly executed original signatures to
the Loan Documents to which it is a party, including this Agreement, the IP
Security Agreement, the Cross-Guaranty, and one or more Control Agreements, with
respect to each Borrower, relative to all Collateral Accounts maintained by such
Borrower with any affiliate of Bank;

          (b) Borrower shall have delivered its Operating Documents and a good
standing certificate of Borrower certified by the Secretary of State of the
State of Delaware as of a date prior to the Effective Date satisfactory to Bank;

          (c) Borrower shall have delivered duly executed original signatures to
the completed Borrowing Resolutions for Borrower;

          (d) Bank shall have received certified copies, dated as of a recent
date, of financing statement searches, as Bank shall request, accompanied by
written evidence (including any UCC termination statements) that the Liens
indicated in any such financing statements either constitute Permitted Liens or
have been or, in connection with the initial Advance, will be terminated or
released;

                                      -3-

<PAGE>

          (e) Borrower shall have delivered the Perfection Certificate executed
by Borrower;

          (f) Borrower shall have delivered evidence satisfactory to Bank that
the insurance policies required by Section 6.7 hereof are in full force and
effect, together with appropriate evidence showing lender loss payable and/or
additional insured clauses or endorsements in favor of Bank;

          (g) Pursuant to the second sentence of Section 5.2A below, Borrower
shall have delivered to Bank evidence (satisfactory to Bank in its good faith
business judgment) of the satisfaction of all such obligations relative to the
Delaware Biolife Judgment and the California Biolife Judgment; and

          (h) Borrower shall have paid the fees and Bank Expenses then due as
specified in Section 2.4 hereof.

     3.2 CONDITIONS PRECEDENT TO ALL CREDIT EXTENSIONS. Bank's obligations to
make each Credit Extension, including the initial Credit Extension, is subject
to the following:

          (a) the representations and warranties in Section 5 shall be true in
all material respects on the date of the request for, and on the Funding Date
of, each Credit Extension; provided, however, that such materiality qualifier
shall not be applicable to any representations and warranties that already are
qualified or modified by materiality in the text thereof; and provided, further
that those representations and warranties expressly referring to a specific date
shall be true, accurate and complete in all material respects as of such date,
and no Default or Event of Default shall have occurred and be continuing or
result from the Credit Extension. Each Credit Extension is Borrower's
representation and warranty on that date that the representations and warranties
in Section 5 remain true in all material respects; provided, however, that such
materiality qualifier shall not be applicable to any representations and
warranties that already are qualified or modified by materiality in the text
thereof; and provided, further that those representations and warranties
expressly referring to a specific date shall be true, accurate and complete in
all material respects as of such date; and

          (b) in Bank's good faith business judgment, there has not been a
Material Adverse Change.

     3.3 COVENANT TO DELIVER.

     Borrower agrees to deliver to Bank each item required to be delivered to
Bank under this Agreement as a condition to any Credit Extension. Borrower
expressly agrees that the extension of a Credit Extension prior to the receipt
by Bank of any such item shall not constitute a waiver by Bank of Borrower's
obligation to deliver such item, and any such extension in the absence of a
required item shall be in Bank's sole discretion.

     3.4 PROCEDURES FOR BORROWING. Subject to the prior satisfaction of all
other applicable conditions to the making of an Advance set forth in this
Agreement, in order for any Borrower to obtain an Advance, Endocare, as agent
for all Borrowers, shall notify Bank (which notice shall be irrevocable) by
electronic mail, facsimile, or telephone by 12:00 p.m. Pacific time on the
Funding Date of the request for such Advance, which notice shall specify on
behalf of which Borrower Endocare is so requesting such Advance. Together with
such notification, Borrower must promptly deliver to Bank by electronic mail or
facsimile a completed Transaction Report executed by a Responsible Officer or
his or her designee. Bank shall credit Advances to the Designated Deposit
Account. Bank may make Advances under this Agreement based on instructions from
a Responsible Officer or his or her designee or without instructions if the
Advances are necessary to meet Obligations which have become due. Bank may rely
on any telephone notice given by a person whom Bank believes is a Responsible
Officer or designee.

     4 CREATION OF SECURITY INTEREST; EARLY TERMINATION OF THIS AGREEMENT

     4.1 GRANT OF SECURITY INTEREST. Each Borrower hereby grants Bank, to secure
the payment and performance in full of all of the Obligations, continuing
security interests in, and pledges to Bank, all right, title, and interest of
such Borrower in and to the Collateral, wherever located, whether now owned or
hereafter acquired or arising, and all proceeds and products thereof. Borrower
represents, warrants, and covenants that the security interests granted herein
are and shall at all times continue to be first priority perfected security
interests in the Collateral (subject in lien priority only to those Permitted
Liens that are expressly entitled to such priority over the

                                      -4-

<PAGE>

security interests of Bank by operation of law or by written subordination
agreement duly executed and delivered by Bank in favor of the holders of such
Permitted Liens). If Borrower shall acquire a commercial tort claim, Borrower
shall promptly notify Bank in a writing signed by Borrower of the general
details thereof. Such notification to Bank shall constitute an additional grant,
hereunder, of a continuing security interest in the commercial tort claim and
all proceeds thereof to Bank, and Borrower shall execute and deliver all such
documents and take all such actions as Bank in its good faith business judgment
may request in connection therewith.

     4.2 EARLY TERMINATION OF THIS AGREEMENT. This Agreement may be terminated
prior to the Maturity Date by Borrower, effective three (3) Business Days after
written notice of termination is given to Bank or if Bank's obligation to fund
Credit Extensions terminates pursuant to the terms of Section 2.1.1(c).
Notwithstanding any such termination, Bank's liens and security interests in the
Collateral shall continue until Borrower pays in full in cash, and otherwise
performs in full, its Obligations. If such termination is at Borrower's election
or at Bank's election due to the occurrence and continuance of an Event of
Default, Borrower shall pay to Bank, in addition to the payment of any other
expenses or fees then-owing, a termination fee in an amount equal to one percent
(1.00%) of the Maximum Revolver Amount; provided that no termination fee shall
be charged if the credit facility hereunder is replaced with a new facility from
another division of Silicon Valley Bank.

     4.3 RELEASE OF BANK'S SECURITY INTERESTS. Upon payment in full in cash, and
otherwise full performance, of the Obligations and at such time as Bank's
obligation to make Credit Extensions has irrevocably terminated, Bank shall
release its liens and security interests in the Collateral and all rights
therein shall revert to Borrower.

     4.4 AUTHORIZATION TO FILE FINANCING STATEMENTS. Borrower hereby authorizes
Bank to file financing statements, without notice to Borrower, with all
appropriate jurisdictions to perfect or protect Bank's interest or rights
hereunder, including a notice that any disposition of the Collateral, by either
Borrower or any other Person, shall be deemed to violate the rights of Bank
under the Code.

     5 REPRESENTATIONS AND WARRANTIES

          Borrower represents and warrants as follows:

     5.1 DUE ORGANIZATION AND AUTHORIZATION. Borrower and each of its
Subsidiaries (subject to the applicable provisions of Section 5.1A below with
respect to any Inactive Subsidiaries) are duly existing and in good standing in
their respective jurisdictions of formation and are qualified and licensed to do
business and are in good standing in any jurisdiction in which the conduct of
their business or their ownership of property requires that they be qualified
except where the failure to do so could not reasonably be expected to have a
material adverse effect on Borrower's business. In connection with this
Agreement, Borrower has delivered to Bank the completed Representations and
Warranties Certificate, dated March 3, 2005, signed by Borrower (as updated in
writing by Borrower to Bank from time to time prior to the Effective Date, the
"PERFECTION CERTIFICATE"). Borrower represents and warrants to Bank that (a)
Borrower's exact legal name is that indicated on the Perfection Certificate and
on the signature page hereof; (b) Borrower is an organization of the type and is
organized in the jurisdiction set forth in the Perfection Certificate; (c) the
Perfection Certificate accurately sets forth Borrower's federal employer
identification number or accurately states that Borrower has none; (d) the
Perfection Certificate accurately sets forth Borrower's place of business, or,
if more than one, its chief executive office as well as Borrower's mailing
address (if different than its chief executive office); (e) Borrower (and each
of its predecessors) has not, in the past five (5) years, changed its state of
formation, organizational structure or type, or any organizational number
assigned by its jurisdiction; and (f) all other information set forth on the
Perfection Certificate pertaining to Borrower and each of its Subsidiaries is
accurate and complete. If Borrower is not now a Registered Organization but
later becomes one, Borrower shall promptly notify Bank of such occurrence and
provide Bank with Borrower's organizational identification number.

     The execution, delivery and performance of the Loan Documents have been
duly authorized, and do not conflict with Borrower's organizational documents,
nor constitute an event of default under any material agreement by which
Borrower is bound. Borrower is not in default under any agreement to which it is
a party or by which it is bound in which the default could reasonably be
expected to have a material adverse effect on Borrower's business.

                                      -5-

<PAGE>

     5.1A ADDITIONAL PROVISIONS RELATIVE TO INACTIVE SUBSIDIARIES. Borrower
hereby represents and warrants that each of Advanced Medical Procedures, Inc., a
Delaware corporation, U.S. Microwave, LLC, a Texas limited liability company,
and Tri-States Cryotherapy, LLC, a Texas limited liability company (individually
and collectively, the "INACTIVE SUBSIDIARIES"): (a) is a wholly-owned Subsidiary
of Endocare; (b) does not have any assets (other than assets that, individually
or in the aggregate, are not material); (c) does not engage in any material
business activity; and (d) currently is in the process of being wound up and
dissolved in accordance with applicable law. Borrower hereby covenants and
agrees, with respect to each Inactive Subsidiary, that, until such Inactive
Subsidiary is wound up and dissolved in accordance with applicable law, Borrower
will not cause, suffer, or permit such Inactive Subsidiary to: (y) have any
assets (other than assets that, individually or in the aggregate, are not
material); or (z) engage in any material business activity. Borrower hereby
further agrees that, with respect to any Inactive Subsidiary as to which Bank
has not received, on or before March 31, 2006, evidence (reasonably satisfactory
to Bank) of the legally effective dissolution thereof, Bank may (in its good
faith business judgment) at any time thereafter require such Inactive Subsidiary
to become a secured Guarantor or an additional co-Borrower under the Loan
Documents, and Borrower agrees to promptly execute and deliver such additional
Loan Documents and take such additional actions (and cause such Inactive
Subsidiary to promptly execute and deliver such additional Loan Documents and
take such additional actions) as Bank may require in its good faith business
judgment to effectuate same.

     5.2 COLLATERAL. Each Borrower has good title to its Collateral, free and
clear of any and all Liens except Permitted Liens. Borrower has no deposit
account other than the deposit accounts with Bank and deposit accounts described
in the Perfection Certificate delivered to Bank in connection herewith.

     The Collateral is not in the possession of any third party bailee (such as
a warehouse), except as expressly identified in the Perfection Certificate.
Except as hereafter disclosed to Bank in writing by Borrower, none of the
components of the Collateral shall be maintained at locations other than as
provided in the Perfection Certificate. In the event that Borrower, after the
date hereof, intends to store or otherwise deliver any portion of the Collateral
to a bailee not otherwise expressly identified (as such a bailee) in the
Perfection Certificate, then Borrower will first notify Bank in writing of such
new bailee. With respect to any bailee of Collateral, Borrower shall, promptly
upon Bank's request therefor, use commercially reasonable efforts to deliver to
Bank a bailee agreement (in form and substance satisfactory to Bank) duly
executed by such bailee. In the event that Bank requests such a bailee agreement
and Borrower uses such efforts but does not succeed in delivering such a bailee
agreement, Bank may (in its good faith business judgment) maintain a Reserve
with respect to such bailee.

     With respect to any leased premises of Borrower, Borrower shall, promptly
upon Bank's request therefor, use commercially reasonable efforts to deliver to
Bank a landlord agreement (in form and substance satisfactory to Bank) duly
executed by the lessor of such leased premises. In the event that Bank requests
such a landlord agreement and Borrower uses such efforts but does not succeed in
delivering such a landlord agreement, Bank may (in its good faith business
judgment) maintain a Reserve with respect to such leased premises.

     All Inventory is in all material respects of good and marketable quality,
free from material defects.

     Borrower is the sole owner of its Intellectual Property, except for
non-exclusive licenses granted to its customers in the ordinary course of
business, and except such other licenses and shared Intellectual Property rights
as expressly described in the Exhibits referred to in the most recent 10K and
10Q reports of Endocare filed with the Securities and Exchange Commission. To
the best of Borrower's knowledge, each Patent is valid and enforceable. No part
of the material Intellectual Property has been judged invalid or unenforceable,
in whole or in part. To the best of Borrower's knowledge, no claim has been made
that any part of the Intellectual Property violates, in any material respect,
the rights of any third party.

     5.2A ADDITIONAL PROVISIONS RELATIVE TO BIOLIFE JUDGMENT. Borrower hereby
represents and warrants that, as of the Effective Date, Borrower has fully
satisfied all obligations of Borrower owing to Biolife Solutions, Inc., a
Delaware corporation ("Biolife") relative to that certain judgment, entered on
October 10, 2003 in the Court of Chancery of the State of Delaware, New Castle
County, in favor of Biolife relative to Case #03J-11-371 E-21-238 and styled
"Biolife Solutions Inc. vs Endocare Inc. (the "Delaware Biolife Judgment") and
filed on January 05, 2004 in the Superior Court of California, Orange County, as
a judgment on sister-state judgment in favor of Biolife with respect to the
Delaware Biolife Judgment (the "California Biolife Judgment"). Concurrently
herewith, Borrower shall deliver to Bank evidence (satisfactory to Bank in its
good faith business judgment) of the satisfaction of all

                                      -6-

<PAGE>

such obligations relative to the Delaware Biolife Judgment and the California
Biolife Judgment. Borrower hereby further covenants and agrees to deliver, on or
before December 31, 2005, evidence (satisfactory to Bank in its good faith
business judgment) of the filing of record of Biolife's acknowledgement of
satisfaction of judgment relative to each of the Delaware Biolife Judgment and
the California Biolife Judgment.

     5.3 ACCOUNTS RECEIVABLE.

          (a) For each Account with respect to which Advances are requested, on
the date each Advance is requested and made, such Account shall meet the Minimum
Eligibility Requirements set forth in Section 13 below.

          (b) All statements made and all unpaid balances appearing in all
invoices, instruments and other documents evidencing the Accounts are and shall
be true and correct in all material respects, and all such invoices, instruments
and other documents, and all of Borrower's Books are genuine and in all respects
what they purport to be. All sales and other transactions underlying or giving
rise to each Account shall comply in all material respects with all applicable
laws and governmental rules and regulations. Borrower has no knowledge of any
actual or imminent Insolvency Proceeding of any Account Debtor whose accounts
include an Eligible Account in any Borrowing Base Certificate. To the best of
Borrower's knowledge, all signatures and endorsements on all documents,
instruments, and agreements relating to all Accounts are genuine, and all such
documents, instruments and agreements are legally enforceable in accordance with
their terms.

     5.4 LITIGATION. There are no actions or proceedings pending or, to the
knowledge of the Responsible Officers, threatened in writing by or against
Borrower or any of its Subsidiaries involving more than $50,000 individually or
$100,000 in the aggregate, other than as expressly disclosed in the most recent
10K and 10Q reports of Endocare filed with the Securities and Exchange
Commission.

     5.5 NO MATERIAL DEVIATION IN FINANCIAL STATEMENTS. All consolidated
financial statements for Endocare and any of its Subsidiaries delivered to Bank
fairly present in all material respects Endocare's consolidated financial
condition and Endocare's consolidated results of operations. There has not been
any material deterioration in Endocare's consolidated financial condition since
the date of the most recent financial statements submitted to Bank.

     5.6 SOLVENCY. The fair salable value of Borrower's assets (including
goodwill minus disposition costs) exceeds the fair value of its liabilities;
Borrower is not left with unreasonably small capital after the transactions in
this Agreement; and Borrower is able to pay its debts (including trade debts) as
they mature.

     5.7 REGULATORY COMPLIANCE. Borrower is not an "investment company" or a
company "controlled" by an "investment company" under the Investment Company Act
of 1940, as amended. Borrower is not engaged as one of its important activities
in extending credit for margin stock (under Regulations T and U of the Federal
Reserve Board of Governors). Borrower has complied in all material respects with
the Federal Fair Labor Standards Act. Borrower has not violated any laws,
ordinances or rules, the violation of which could reasonably be expected to have
a material adverse effect on its business. None of Borrower's or any of its
Subsidiaries' properties or assets has been used by Borrower or any Subsidiary
or, to the best of Borrower's knowledge, by previous Persons, in disposing,
producing, storing, treating, or transporting any hazardous substance other than
legally. Borrower and each of its Subsidiaries have obtained all consents,
approvals and authorizations of, made all declarations or filings with, and
given all notices to, all government authorities that are necessary in all
material respects to continue its business as currently conducted.

     5.8 SUBSIDIARIES; INVESTMENTS. Borrower does not own any stock, partnership
interest or other equity securities except for Permitted Investments.

     5.9 TAX RETURNS AND PAYMENTS; PENSION CONTRIBUTIONS. Except as expressly
disclosed in the most recent 10K and 10Q reports of Endocare filed with the
Securities and Exchange Commission, Borrower has timely filed all required tax
returns and reports, and Borrower has timely paid all foreign, federal, state
and local taxes, assessments, deposits and contributions owed by Borrower.
Borrower may defer payment of any contested taxes, provided that Borrower (a) in
good faith contests its obligation to pay the taxes by appropriate proceedings
promptly and diligently instituted and conducted, (b) notifies Bank in writing
of the commencement of, and any material development in, the proceedings, (c)
posts bonds or takes any other steps required to prevent the governmental

                                      -7-

<PAGE>

authority levying such contested taxes from obtaining a Lien upon any of the
Collateral that is other than a "Permitted Lien". Except as expressly disclosed
in the most recent 10K and 10Q reports of Endocare filed with the Securities and
Exchange Commission, Borrower is unaware of any claims or adjustments proposed
for any of Borrower's prior tax years which could result in additional taxes
becoming due and payable by Borrower. Borrower has paid all amounts necessary to
fund all present pension, profit sharing and deferred compensation plans in
accordance with their terms, and Borrower has not withdrawn from participation
in, and has not permitted partial or complete termination of, or permitted the
occurrence of any other event with respect to, any such plan which could
reasonably be expected to result in any liability of Borrower, including any
liability to the Pension Benefit Guaranty Corporation or its successors or any
other governmental agency.

     5.10 USE OF PROCEEDS. Borrower shall use the proceeds of the Credit
Extensions solely as working capital, and to fund its general business
requirements and not for personal, family, household or agricultural purposes.

     5.11 FULL DISCLOSURE. No written representation, warranty or other
statement of Borrower in any certificate or written statement given to Bank, as
of the date such representations, warranties, or other statements were made,
taken together with (i) all such written certificates and written statements
given to Bank and (ii) all periodic filings of Endocare with the Securities and
Exchange Commission, contains any untrue statement of a material fact or omits
to state a material fact necessary to make the statements contained in the
certificates or statements not misleading (it being recognized by Bank that the
projections and forecasts provided by Borrower in good faith and based upon
reasonable assumptions are not viewed as facts and that actual results during
the period or periods covered by such projections and forecasts may differ from
the projected or forecasted results).

     6 AFFIRMATIVE COVENANTS

          Borrower shall do all of the following:

     6.1 GOVERNMENT COMPLIANCE. Subject to the applicable provisions of Section
5.1A above with respect to any Inactive Subsidiary: (a) maintain its and all its
Subsidiaries' legal existence and good standing in their respective
jurisdictions of formation and maintain qualification in each jurisdiction in
which the failure to so qualify would reasonably be expected to have a material
adverse effect on Borrower's business or operations; and (b) comply, and cause
each Subsidiary to comply, with all laws, ordinances and regulations to which it
is subject, noncompliance with which could have a material adverse effect on
Borrower's business.

     6.2 FINANCIAL STATEMENTS, REPORTS, CERTIFICATES.

          (a) Borrower shall provide Bank with the following:

          (i) a Transaction Report, within fifteen (15) days after the end of
each month and at the time of each Advance request; provided, however, that
while Phase II is in effect, Transaction Reports shall be provided each week as
well as at the time of each Advance request;

          (ii) within fifteen (15) days after the end of each month, (A) monthly
accounts receivable agings, aged by invoice date, (B) monthly accounts payable
agings, aged by invoice date, and outstanding or held check registers, if any,
(C) monthly reconciliations of accounts receivable agings (aged by invoice
date), Transaction Reports, and general ledger, (D) monthly perpetual inventory
reports for Inventory valued on a first-in, first-out basis at the lower of cost
or market (in accordance with GAAP) or such other inventory reports as are
requested by Bank in its good faith business judgment, and (E) monthly Deferred
Revenue reports;

          (iii) as soon as available, and in any event within thirty (30) days
after the end of each month, monthly unaudited financial statements;

          (iv) within thirty (30) days after the end of each month a monthly
Compliance Certificate signed by a Responsible Officer, and such other
information as Bank shall reasonably request; and

          (v) within thirty (30) days prior to the end of each fiscal year of
Borrower, (A) annual operating budgets (including income statements, balance
sheets and cash flow statements, by month) for the upcoming fiscal year of
Borrower, and (B) annual financial projections for the following fiscal year (on
a quarterly basis) as

                                      -8-

<PAGE>

approved by Borrower's board of directors, together with any related business
forecasts used in the preparation of such annual financial projections.

          (b) Borrower shall deliver to Bank: (i) as soon as available, but no
later than five (5) days after filing with the Securities Exchange Commission,
Endocare's 10K, 10Q, and 8K reports; (ii) a Compliance Certificate together with
delivery of the 10K and 10Q reports; (iii) a prompt report of any legal actions
pending or threatened against Borrower or any Subsidiary that could result in
damages or costs to Borrower or any Subsidiary of more than $50,000 individually
or $100,000 in the aggregate; and (iv) budgets, sales projections, operating
plans or other financial information Bank reasonably requests. Endocare's 10K,
10Q, and 8K reports required to be delivered pursuant to Section 6.2(b)(i) shall
be deemed to have been delivered on the date on which Endocare posts such report
or provides a link thereto on Borrower's or another website on the Internet;
provided, that Endocare shall provide paper copies to Bank of the Compliance
Certificates required by Section 6.2(b)(ii).

          (c) Borrower shall provide Bank: (i) prompt written notice (as soon as
reasonably practicable and in any event within 30 days) of any material change
in the composition of the Intellectual Property, (ii) prior written notice (in
accordance with Section 6.10) of the registration (or filed application for
registration) of any Copyright, including any subsequent ownership right of
Borrower in or to any Copyright, Patent or Trademark not previously disclosed in
writing to Bank, or (iii) prompt written notice (as soon as reasonably
practicable and in any event within 30 days) of Borrower's knowledge of an event
that materially adversely affects the value of the Intellectual Property.

          (d) With respect to the financial statements referred to above,
Borrower agrees to deliver financial statements prepared on both a consolidated
and consolidating basis and agrees that no Borrower or subsidiary of Borrower
will have a fiscal year different from that of Endocare. Endocare's fiscal year
ends on December 31 of each year.

     6.3 Accounts Receivable.

          (a) Schedules and Documents Relating to Accounts. Borrower shall
deliver to Bank Transaction Reports and schedules of collections, as provided in
Section 6.2, on Bank's standard forms; provided, however, that Borrower's
failure to execute and deliver the same shall not affect or limit Bank's Liens
and other rights in all of Borrower's Accounts, nor shall Bank's failure to
advance or lend against a specific Account affect or limit Bank's Lien and other
rights therein. If requested by Bank, Borrower shall furnish Bank with copies
(or, at Bank's request, originals) of all contracts, orders, invoices, and other
similar documents, and all shipping instructions, delivery receipts, bills of
lading, and other evidence of delivery, for any goods the sale or disposition of
which gave rise to such Accounts. In addition, Borrower shall deliver to Bank,
on its request, the originals of all instruments, chattel paper, security
agreements, guarantees and other documents and property evidencing or securing
any Accounts, in the same form as received, with all necessary indorsements, and
copies of all credit memos.

          (b) Disputes. Borrower shall promptly notify Bank of all disputes or
claims, in excess of $50,000 individually or in the aggregate at any one time,
relating to Accounts. Borrower may forgive (completely or partially),
compromise, or settle any Account for less than payment in full, or agree to do
any of the foregoing so long as (i) Borrower does so in good faith, in a
commercially reasonable manner, in the ordinary course of business, in
arm's-length transactions, and reports the same to Bank in the regular reports
provided to Bank; (ii) no Default or Event of Default has occurred and is
continuing; and (iii) after taking into account all such discounts, settlements
and forgiveness, the total outstanding Advances will not exceed the lesser of
the Maximum Revolver Amount or the Borrowing Base.

          (c) Collection of Accounts. Borrower shall have the right to collect
all Accounts, unless and until a Default or an Event of Default has occurred and
is continuing. Whether or not an Event of Default has occurred and is
continuing, Borrower shall hold all payments on, and proceeds of, Accounts in
trust for Bank, and Borrower shall immediately deliver all such payments and
proceeds to Bank in their original form, duly endorsed, to be applied to the
Obligations pursuant to the terms of Section 9.4 hereof. Bank may, in its good
faith business judgment, require that all proceeds of Accounts be deposited by
Borrower into a lockbox account, or such other "blocked account" as Bank may
specify, pursuant to a blocked account agreement in such form as Bank may
specify in its good faith business judgment.

                                      -9-

<PAGE>

          (d) Returns. Provided no Event of Default has occurred and is
continuing, if any Account Debtor returns any Inventory to Borrower, Borrower
shall promptly (i) determine the reason for such return, (ii) issue a credit
memorandum to the Account Debtor in the appropriate amount, and (iii) provide a
copy of such credit memorandum to Bank, upon request from Bank. In the event any
attempted return occurs after the occurrence and during the continuance of any
Event of Default, Borrower shall hold the returned Inventory in trust for Bank,
and immediately notify Bank of the return of the Inventory.

          (e) Verification. Bank may, from time to time, verify directly with
the respective Account Debtors the validity, amount and other matters relating
to the Accounts, either in the name of Borrower or Bank or such other name as
Bank may choose.

          (f) No Liability. Bank shall not be responsible or liable for any
shortage or discrepancy in, damage to, or loss or destruction of, any goods, the
sale or other disposition of which gives rise to an Account, or for any error,
act, omission, or delay of any kind occurring in the settlement, failure to
settle, collection or failure to collect any Account, or for settling any
Account in good faith for less than the full amount thereof, nor shall Bank be
deemed to be responsible for any of Borrower's obligations under any contract or
agreement giving rise to an Account. Nothing herein shall, however, relieve Bank
from liability for its own gross negligence or willful misconduct.

     6.4 REMITTANCE OF PROCEEDS. Except as otherwise provided in Section 6.3(c),
deliver, in kind, all proceeds arising from the disposition of any Collateral to
Bank in the original form in which received by Borrower not later than the
following Business Day after receipt by Borrower, to be applied to the
Obligations pursuant to the terms of Section 9.4 hereof; provided that, if no
Default or Event of Default has occurred and is continuing, Borrower shall not
be obligated to remit to Bank the proceeds of the sale of worn out or obsolete
Equipment disposed of by Borrower in good faith in an arm's length transaction
for an aggregate purchase price of $100,000 or less (for all such transactions
in any fiscal year). Borrower agrees that it will not commingle proceeds of
Collateral with any of Borrower's other funds or property, but will hold such
proceeds separate and apart from such other funds and property and in an express
trust for Bank. Nothing in this Section limits the restrictions on disposition
of Collateral set forth elsewhere in this Agreement.

     6.5 TAXES; PENSIONS. (a) Timely file all required tax returns and reports
and timely pay all material foreign, federal, state and local taxes,
assessments, deposits and contributions owed by Borrower except (i) for deferred
payment of any taxes contested pursuant to the terms of Section 5.9 hereof, and
(ii) as expressly disclosed in the most recent 10K and 10Q reports of Endocare
filed with the Securities and Exchange Commission. (b) Pay all amounts necessary
to fund all present pension, profit sharing and deferred compensation plans in
accordance with their terms.

     6.6 ACCESS TO COLLATERAL; BOOKS AND RECORDS. At reasonable times, on at
least one (1) Business Day's notice (provided no notice is required if a Default
or Event of Default has occurred and is continuing), Bank, or its agents, shall
have the right to inspect the Collateral and the right to audit and copy
Borrower's Books, subject to Bank's applicable confidentiality obligations in
Section 12.9. The foregoing inspections and audits shall be at Borrower's
expense, and the charge therefor shall be $750 per person per day (or such
higher amount as shall represent Bank's then-current standard charge for the
same), plus reasonable out-of-pocket expenses. In the event Borrower and Bank
schedule an audit more than five (5) days in advance, and Borrower cancels or
seeks to reschedules the audit with less than five (5) days written notice to
Bank, then (without limiting any of Bank's rights or remedies), Borrower shall
pay Bank a fee of $1,000 plus any out-of-pocket expenses incurred by Bank to
compensate Bank for the anticipated costs and expenses of the cancellation or
rescheduling.

     6.7 INSURANCE. Keep its business and the Collateral insured for risks and
in amounts standard for companies in Borrower's industry and location and as
Bank may reasonably request. Insurance policies shall be in a form, with
companies that are satisfactory to Bank. All property policies shall have a
lender's loss payable endorsement showing Bank as lender loss payee and waive
subrogation against Bank, and all liability policies shall show, or have
endorsements showing, Bank as an additional insured. All policies (or the lender
loss payable and additional insured endorsements) shall provide that the insurer
must give Bank at least twenty (20) days notice before canceling, amending, or
declining to renew its policy. At Bank's request, Borrower shall deliver
certified copies of policies and evidence of all premium payments. Proceeds
payable under any policy shall, at Bank's option, be payable to Bank on account
of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of

                                      -10-

<PAGE>

Default has occurred and is continuing, Borrower shall have the option of
applying the proceeds of any casualty policy up to $100,000, in the aggregate,
toward the replacement or repair of destroyed or damaged property; provided that
any such replaced or repaired property (i) shall be of equal or like value as
the replaced or repaired Collateral and (ii) shall be deemed Collateral in which
Bank has been granted a first priority security interest (subject in lien
priority only to those Permitted Liens that are expressly entitled to such
priority over the security interests of Bank by operation of law or by written
subordination agreement duly executed and delivered by Bank in favor of the
holders of such Permitted Liens), and (b) after the occurrence and during the
continuance of an Event of Default, all proceeds payable under such casualty
policy shall, at the option of Bank, be payable to Bank on account of the
Obligations. If Borrower fails to obtain insurance as required under this
Section 6.7 or to pay any amount or furnish any required proof of payment to
third persons and Bank, Bank may make all or part of such payment or obtain such
insurance policies required in this Section 6.7, and take any action under the
policies Bank deems prudent.

     6.8 OPERATING ACCOUNTS.

          (a) Maintain its primary depository and operating accounts and
securities accounts with Bank and Bank's affiliates, which accounts shall
represent at least 85% of the dollar value of Borrower's accounts at all
financial institutions. For each Collateral Account that Borrower at any time
maintains with Bank's affiliates, Borrower, Bank, and such affiliate of Bank
shall enter into a Control Agreement or other appropriate instrument with
respect to such Collateral Account to perfect Bank's Lien in such Collateral
Account in accordance with the terms hereunder.

          (b) Provide Bank five (5) days prior written notice before
establishing any Collateral Account at or with any bank or financial institution
other than Bank or its Affiliates. Upon the occurrence and during the
continuation of an Event of Default, if Bank so requests, for each Collateral
Account that Borrower at any time maintains (other than Collateral Accounts
maintained with Bank or Bank's affiliates), Borrower shall cause such applicable
bank or financial institution at or with which such Collateral Account is
maintained to execute and deliver a Control Agreement or other appropriate
instrument with respect to such Collateral Account to perfect Bank's Lien in
such Collateral Account in accordance with the terms hereunder. The provisions
of the previous sentence shall not apply to deposit accounts exclusively used
for payroll, payroll taxes and other employee wage and benefit payments to or
for the benefit of Borrower's employees and identified to Bank by Borrower as
such.

     6.9 FINANCIAL COVENANTS.

          Endocare shall maintain at all times, compliance to be determined as
of the last day of each month (unless otherwise expressly noted below), on a
consolidated basis with respect to Endocare and its Subsidiaries:

          (a) Tangible Net Worth. A Tangible Net Worth of at least the sum of
the following (the "REQUIRED TNW AMOUNT"): (a) the TNW Base Amount (as defined
below), plus (b) 25% of all consideration received after the Effective Date for
issuances of Endocare's equity securities and the principal amount of
Subordinated Debt of the Borrower, plus (c) 25% of the Endocare's positive
consolidated Net Income in each fiscal quarter ending after the Effective Date.

As used herein, the term "TNW BASE AMOUNT" means, as of any date of
determination: (a) $2,000,000 at all times during the period commencing on the
Effective Date and ending on December 31, 2005; and (b) $1,000,000 at all times
from and after January 1, 2006.

Increases in the Required TNW Amount based on consideration received for equity
securities and Subordinated Debt of the Borrower shall be effective as of the
end of the month in which such consideration is received, and shall continue
effective thereafter. Increases in the Required TNW Amount based on Net Income
shall be effective on the last day of the fiscal quarter in which such Net
Income is realized, and shall continue effective thereafter. In no event (except
for step-downs in the TNW Base Amount as expressly set forth in the definition
thereof) shall the Required TNW Amount be decreased from one fiscal period to
another subsequent fiscal period.

     6.10 PROTECTION AND REGISTRATION OF INTELLECTUAL PROPERTY RIGHTS. Borrower
shall: (a) protect, defend and maintain the validity and enforceability of its
Intellectual Property; (b) promptly advise Bank in writing of material
infringements of its material Intellectual Property; and (c) not allow any
Intellectual Property material to

                                      -11-
<PAGE>

Borrower's business to be abandoned, forfeited or dedicated to the public
without Bank's written consent (which consent shall not be unreasonable withheld
if no Event of Default has occurred and is continuing or would result from such
abandonment, forfeiture, or dedication to the public). Concurrently herewith,
Borrower shall execute and deliver to Bank the IP Security Agreement. Exhibit A
attached to the IP Security Agreement identifies, as of the Effective Date, any
and all of Borrower's maskworks, computer software, or other copyrights of
Borrower that are registered (or the subject of an application for registration)
with the United States Copyright Office (collectively, the "Existing Registered
Copyrights"). Except for the Existing Copyright Registrations, Borrower will NOT
register with the United States Copyright Office (or apply for such registration
of) any of Borrower's maskworks, computer software, or other copyrights, unless
Borrower: (x) provides Bank with at least fifteen (15) days prior written notice
of its intent to register such copyrights or mask works together with a copy of
the application it intends to file with the United States Copyright Office
(excluding exhibits thereto); (y) executes an intellectual property security
agreement or such other documents as Bank may reasonably request to maintain the
perfection and priority of Bank's security interest in the copyrights or mask
works intended to be registered with the United States Copyright Office; and (z)
record such intellectual property security agreement with the United States
Copyright Office contemporaneously with filing the copyright or mask work
application(s) with the United States Copyright Office. Borrower shall promptly
provide to Bank a copy of the application(s) filed with the United States
Copyright Office together with evidence of the recording of the intellectual
property security agreement necessary for Bank to maintain the perfection and
priority of its security interest in such copyrights or mask works. Borrower
shall provide written notice to Bank of any application filed by Borrower in the
United States Patent and Trademark Office for a patent or to register a
trademark or service mark within 30 days after any such filing.

     6.11 LITIGATION COOPERATION. From the date hereof and continuing through
the termination of this Agreement, make available to Bank, without expense to
Bank, Borrower and its officers, employees and agents and Borrower's books and
records, to the extent that Bank may deem them reasonably necessary to prosecute
or defend any third-party suit or proceeding instituted by or against Bank with
respect to any Collateral or relating to Borrower.

     6.12 [INTENTIONALLY OMITTED]

     6.13 [INTENTIONALLY OMITTED]

     6.14 FURTHER ASSURANCES. Borrower shall execute any further instruments and
take further action as Bank reasonably requests to perfect or continue Bank's
Lien in the Collateral or to effect the purposes of this Agreement.

     7 NEGATIVE COVENANTS

     Borrower shall not do any of the following without Bank's prior written
consent:

     7.1 DISPOSITIONS. (a) Convey, sell, lease, transfer or otherwise dispose of
(collectively, "TRANSFER"), or permit any of its Subsidiaries to Transfer, all
or any part of its business or property, except for Transfers (i) of Inventory
in the ordinary course of business; (ii) of worn-out or obsolete Equipment;
(iii) constituting Permitted Liens or Permitted Investments; (iv) of
non-exclusive licenses (or similar non-exclusive arrangements) for the use of
the property of Borrower or its Subsidiaries in the ordinary course of business;
and (v) constituting Permitted Exclusive Licensing Transactions.

          (b) (i) Anything herein or in the other Loan Documents to the contrary
notwithstanding, Bank agrees that, subject to the terms and conditions of this
Section 7.1(b), Bank shall not unreasonably withhold its consent to a sale by
Endocare of all of the issued and outstanding capital stock of TIMM to a bona
fide third-party purchaser that is not affiliated with any Borrower or
Subsidiary thereof (a "TIMM Stock Sale"), or a sale by TIMM of all or
substantially all of TIMM's assets to a bona fide third-party purchaser that is
not affiliated with any Borrower or Subsidiary thereof (a "TIMM Asset Sale"). As
used herein, the term "TIMM Sale" means a TIMM Stock Sale or a TIMM Asset Sale,
as the case may be.

               (ii) Borrower agrees to provide Bank with (y) prior written
notice of any proposed TIMM Sale, which notice shall be reasonably detailed as
to the terms and conditions of such proposed TIMM Sale (including a detailed
description of the consideration to be received by Borrower in respect thereof
and, if such

                                      -12-

<PAGE>

proposed TIMM Sale is a proposed TIMM Asset Sale, a detailed list of the assets
of TIMM to be sold pursuant thereto), and (z) such other information regarding
such proposed TIMM Sale as Bank may reasonably request, as promptly as
practicable and in any event not less that 10 Business Days prior to the
proposed consummation of such proposed TIMM Sale. Bank agrees to respond, to
Borrower's written request for Bank's consent to a proposed TIMM Sale, not later
than 10 Business Days following Bank's receipt of the notice and information
described in clauses (y) and (z) above. Borrower and Bank expressly acknowledge
that Bank need not consent to any proposed TIMM Sale, if an Event of Default has
occurred and is continuing at the time of Borrower's request therefore or at the
proposed time of consummation thereof, or would result from the consummation
thereof.

               (iii) All consideration, consisting of net cash proceeds, paid or
payable to Borrower in respect of the proposed TIMM Sale shall be promptly
delivered to Bank for application to the Obligations (with the excess, if any,
to be deposited into one or more Deposit Accounts of Borrower maintained at
Bank). All consideration, other than cash proceeds, paid or payable to Borrower
in respect of the proposed TIMM Sale shall constitute additional Collateral
subject to Bank's first priority perfected security interests therein (subject
in lien priority only to those Permitted Liens that are expressly entitled to
such priority over the security interests of Bank by operation of law or by
written subordination agreement duly executed and delivered by Bank in favor of
the holders of such Permitted Liens) and, upon request of Bank, shall be
promptly delivered to Bank.

               (iv) With respect to any proposed TIMM Asset Sale to which Bank
consents in writing (an "Approved TIMM Asset Sale"), Bank agrees, concurrently
with the consummation thereof and the satisfaction of the applicable
requirements set forth in this Section 7.1(b) relating thereto, to release
Bank's security interests (without recourse, representation, or warranty) in the
assets sold pursuant to the Approved TIMM Asset Sale (but not the proceeds of
such assets paid or payable pursuant to the terms of the Approved TIMM Asset
Sale), to authenticate and authorize (at Borrower's expense) the filing of
applicable UCC Releases (in form and substance satisfactory to Bank) relative to
such sold assets, and to execute and deliver (at Borrower's expenses) such other
similar documents (in form and substance satisfactory to Bank), or to take such
other actions, as Borrower may reasonable request in writing in order to effect
or reflect such release of Bank's security interests in such assets.

               (v) With respect to any proposed TIMM Stock Sale to which Bank
consents in writing (an "Approved TIMM Stock Sale"), Bank agrees, concurrently
with the consummation thereof and the satisfaction of the applicable
requirements set forth in this Section 7.1(b) relating thereto, to release
Bank's security interests (without recourse, representation, or warranty) in the
capital stock of TIMM sold by Endocare pursuant to the Approved TIMM Stock Sale
and in the assets of TIMM (but not the proceeds of such capital stock paid or
payable pursuant to the terms of the Approved TIMM Stock Sale), to authenticate
and authorize (at Borrower's expense) the filing of applicable UCC Releases (in
form and substance satisfactory to Bank) relative to such sold capital stock and
the assets of TIMM, and to execute and deliver (at Borrower's expenses) such
other similar documents, or to take such other actions, as Borrower may
reasonable request in writing in order to effect or reflect such release of
Bank's security interests in such sold capital stock and such assets of TIMM.
Concurrently with the consummation of the Approved TIMM Stock Sale and the
satisfaction of the applicable requirements set forth in this Section 7.1(b)
relating thereto, TIMM thereafter shall no longer be a co-Borrower (or guarantor
relative to any other Borrower) and shall be released from its Obligations owing
to Bank under the Loan Documents (except for indemnification obligations
pursuant to the Loan Documents, which shall survive the Approved TIMM Stock
Sale), and Bank agrees to execute and deliver (at Borrower's expenses) such Loan
Documents (in form and substance satisfactory to Bank), or to take such other
actions, as Borrower may reasonable request in writing in order to effect or
reflect same.

     7.2 CHANGES IN BUSINESS; CHANGE IN CONTROL; BUSINESS LOCATIONS. Engage in
any material line of business other than those lines of business conducted by
Borrower and its Subsidiaries on the date hereof and any businesses reasonably
related, complementary or incidental thereto or reasonable extensions thereof.
Borrower shall not cause, permit or suffer any Change in Control. Borrower shall
not, without at least fifteen (15) days prior written notice to Bank: (1) add
any new offices or business locations, including warehouses (unless Borrower's
assets or property located at such new offices or business locations have a
value less than One Hundred Thousand Dollars ($100,000) in the aggregate), (2)
change its jurisdiction of organization, (3) change its organizational structure
or type, (4) change its legal name, or (5) change any organizational number (if
any) assigned by its jurisdiction of organization.

     7.3 MERGERS OR ACQUISITIONS. (a) Merge or consolidate, or permit any of its
Subsidiaries to merge or consolidate, with any other Person, or acquire, or
permit any of its Subsidiaries to acquire, all or substantially all of

                                      -13-

<PAGE>

the capital stock or property of another Person. A Subsidiary (that is not a
Borrower) may merge or consolidate into another Subsidiary (that is not a
Borrower).

          (b) Anything in Section 7.3(a) to the contrary notwithstanding, a
Borrower (other than Endocare) or a Subsidiary of Borrower may merge with and
into another Borrower, if the following conditions are satisfied: (i) no Default
or Event of Default has occurred and is continuing at the time of such merger,
or would result after giving effect to such merger; (ii) a Borrower is the
surviving entity of such merger; (iii) the transactions permitted under this
Section 7.3(b) do not exceed $100,000 in the aggregate in any fiscal year; (iv)
Bank shall have received lien searches listing all effective financing
statements which name the disappearing entity of such merger as debtor that are
filed in the applicable filing offices, none of which financing statements shall
cover any of the assets of such disappearing entity, except (x) Permitted Liens,
(y) financing statements as to which Bank has received evidence satisfactory to
Bank of the confirmed termination thereof (or Bank has received duly executed
written authorization, in form and substance satisfactory to Bank, from the
appropriate parties to terminate such financing statements), or (z) as otherwise
agreed in writing by Bank; and (v) Bank shall have received such other
information (if any) as Bank may reasonably request relative to such proposed
merger.

     7.4  INDEBTEDNESS.

          (a) Create, incur, assume, or be liable for any Indebtedness, or
permit any Subsidiary to do so, other than Permitted Indebtedness.

          (b) Without limiting the generality of Section 7.4(a), all present and
future indebtedness of Borrower to its officers, directors, and equityholders
("Inside Debt") shall, at all times, be subordinated to the Obligations pursuant
to a subordination agreement on Bank's standard form. Borrower represents and
warrants that there is no Inside Debt presently outstanding, except for the
following: NONE. Prior to incurring any Inside Debt in the future, Borrower
shall cause the person to whom such Inside Debt will be owed to execute and
deliver to Bank a subordination agreement on Bank's standard form.

     7.5 ENCUMBRANCE. Create, incur, or allow any Lien on any of the Collateral,
or assign or convey any right to receive income, including the sale of any
Accounts, or permit any of its Subsidiaries to do so, except for Permitted
Liens, permit any Collateral not to be subject to the first priority security
interests of Bank therein (subject in lien priority only to those Permitted
Liens that are expressly entitled to such priority over the security interests
of Bank by operation of law or by written subordination agreement duly executed
and delivered by Bank in favor of the holders of such Permitted Liens), or enter
into any agreement, document, instrument or other arrangement (except with or in
favor of Bank) with any Person which directly or indirectly prohibits or has the
effect of prohibiting Borrower or any Subsidiary from assigning, mortgaging,
pledging, granting a security interest in or upon, or encumbering any of
Borrower's or any Subsidiary's Intellectual Property, except as is otherwise
permitted in Section 7.1 hereof and the definition of "Permitted Lien" herein.

     7.6 MAINTENANCE OF COLLATERAL ACCOUNTS. Maintain any Collateral Account
except pursuant to the terms of Section 6.8.(b) hereof.

     7.7 INVESTMENTS; DISTRIBUTIONS.

          (a) Directly or indirectly make any Investment other than Permitted
Investments, or permit any of its Subsidiaries to do so.

          (b) Pay any dividends or make any distribution or payment or redeem,
retire or purchase any capital stock; provided that: (i) Borrower may convert
any of its convertible securities into other securities pursuant to the terms of
such convertible securities or otherwise in exchange thereof, (ii) Borrower may
pay dividends solely in common stock; (iii) one Borrower may pay dividends to
another Borrower; and (iv) Borrower may repurchase the stock of former
employees, directors, or consultants pursuant to stock repurchase agreements so
long as an Event of Default does not exist at the time of such repurchase and
would not exist after giving effect to such repurchase, provided such repurchase
does not exceed in the aggregate of $50,000 per fiscal year.

                                      -14-

<PAGE>

     7.8 TRANSACTIONS WITH AFFILIATES. Directly or indirectly enter into or
permit to exist any material transaction with any Affiliate of Borrower, except
for transactions that are in the ordinary course of Borrower's business, upon
fair and reasonable terms that are no less favorable to Borrower than would be
obtained in an arm's length transaction with a non-affiliated Person.

     7.9 SUBORDINATED DEBT. (a) Make or permit any payment on any Subordinated
Debt, except under the terms of the subordination, intercreditor, or other
similar agreement to which such Subordinated Debt is subject, or (b) amend any
provision in any document relating to the Subordinated Debt which would increase
the amount thereof or adversely affect the subordination thereof to Obligations
owed to Bank.

     7.10 COMPLIANCE. Become an "investment company" or a company controlled by
an "investment company", under the Investment Company Act of 1940 or undertake
as one of its important activities extending credit to purchase or carry margin
stock (as defined in Regulation U of the Board of Governors of the Federal
Reserve System), or use the proceeds of any Credit Extension for that purpose;
fail to meet the minimum funding requirements of ERISA, permit a Reportable
Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply
with the Federal Fair Labor Standards Act or violate any other law or
regulation, if the violation could reasonably be expected to have a material
adverse effect on Borrower's business, or permit any of its Subsidiaries to do
so; withdraw or permit any Subsidiary to withdraw from participation in, permit
partial or complete termination of, or permit the occurrence of any other event
with respect to, any present pension, profit sharing and deferred compensation
plan which could reasonably be expected to result in any liability of Borrower,
including any liability to the Pension Benefit Guaranty Corporation or its
successors or any other governmental agency.

     8 EVENTS OF DEFAULT

     Any one of the following shall constitute an event of default (an "EVENT OF
DEFAULT") under this Agreement:

     8.1 PAYMENT DEFAULT. Borrower fails to (a) make any payment of principal or
interest on any Credit Extension on its due date, or (b) pay any other
Obligations within five (5) Business Days after such Obligations are due and
payable. During the cure period, the failure to cure the payment default is not
an Event of Default (but no Credit Extension will be made during the cure
period);

     8.2 COVENANT DEFAULT.

          (a) Borrower fails or neglects to perform any obligation in one or
more of Sections 6.2, 6.3, 6.8, or 6.9, or violates any covenant in Section 7;
or

          (b) Borrower fails or neglects to perform, keep, or observe any other
term, provision, condition, covenant or agreement contained in this Agreement or
any Loan Documents, and as to any default (other than those specified in Section
8 below) under such other term, provision, condition, covenant or agreement that
can be cured, has failed to cure the default within ten (10) days after the
occurrence thereof; provided, however, that if the default cannot by its nature
be cured within the ten (10) day period or cannot after diligent attempts by
Borrower be cured within such ten (10) day period, and such default is likely to
be cured within a reasonable time, then Borrower shall have an additional period
(which shall not in any case exceed thirty (30) days) to attempt to cure such
default, and within such reasonable time period the failure to cure the default
shall not be deemed an Event of Default (but no Credit Extensions shall be made
during such cure period). Grace periods provided under this section shall not
apply, among other things, to financial covenants or any other covenants set
forth in subsection (a) above;

     8.3 MATERIAL ADVERSE CHANGE. A Material Adverse Change occurs;

     8.4 ATTACHMENT. (a) Any material portion of Borrower's assets is attached,
seized, levied on, or comes into possession of a trustee or receiver and the
attachment, seizure or levy is not removed in ten (10) days; (b) the service of
process upon Borrower seeking to attach, by trustee or similar process, any
funds of Borrower on deposit with Bank, or any entity under control of Bank
(including a subsidiary); (c) Borrower is enjoined, restrained, or prevented by
court order from conducting a material part of its business; (d) a judgment or
other claim in excess of $50,000 becomes a Lien on any of Borrower's assets; or
(e) a notice of lien, levy, or assessment is filed against any of Borrower's
assets by any government agency and not paid within ten (10) days after Borrower
receives

                                      -15-

<PAGE>

notice. These are not Events of Default if stayed or if a bond is posted pending
contest by Borrower (but Bank shall have no obligation to make any Credit
Extensions during such cure period);

     8.5 INSOLVENCY. (a) Borrower is unable to pay its debts (including trade
debts) as they become due or otherwise becomes insolvent; (b) Borrower begins an
Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower
and not dismissed or stayed within thirty (30) days (but no Credit Extensions
shall be made while of any of the conditions described in clause (a) exist
and/or until any Insolvency Proceeding is dismissed);

     8.6 OTHER AGREEMENTS. There is a default in any agreement to which Borrower
or any Guarantor is a party with a third party or parties resulting in a right
by such third party or parties, whether or not exercised, to accelerate the
maturity of any Indebtedness in an amount in excess of Fifty Thousand Dollars
($50,000) or that could have a material adverse effect on Borrower's or any
Guarantor's business;

     8.7 JUDGMENTS. A judgment or judgments for the payment of money in an
amount, individually or in the aggregate, of at least Fifty Thousand Dollars
($50,000) (not covered by independent third-party insurance) shall be rendered
against Borrower and shall remain unsatisfied and unstayed for a period of ten
(10) days after the entry thereof (provided that no Credit Extensions will be
made prior to the satisfaction or stay of such judgment);

     8.8 MISREPRESENTATIONS. Borrower or any Person acting for Borrower makes
any representation, warranty, or other statement now or later in this Agreement,
any Loan Document or in any writing delivered to Bank or to induce Bank to enter
this Agreement or any Loan Document, and such representation, warranty, or other
statement is incorrect in any material respect when made;

     8.9 SUBORDINATED DEBT. A default or breach in any material respect occurs
under any agreement between Borrower and any creditor of Borrower that signed a
subordination, intercreditor, or other similar agreement with Bank, or any
creditor that has signed such an agreement with Bank breaches in any material
respect any terms of such agreement; or

     8.10 GUARANTY. (a) Any guaranty of any Obligations terminates or ceases for
any reason to be in full force and effect; (b) any Guarantor does not perform
any obligation or covenant under any guaranty of the Obligations; (c) any
circumstance described in Sections 8.3, 8.4, 8.5, 8.7, or 8.8. occurs with
respect to any Guarantor, (d) the liquidation, winding up, or termination of
existence of any Guarantor; or (e) (i) a material impairment in the perfection
or priority of Bank's Lien in the collateral provided by Guarantor or in the
value of such collateral or (ii) a material adverse change in the general
affairs, management, results of operation, condition (financial or otherwise) or
the prospect of repayment of the Obligations occurs with respect to any
Guarantor.

     9    BANK'S RIGHTS AND REMEDIES

     9.1 RIGHTS AND REMEDIES. While an Event of Default occurs and continues
Bank may, without notice or demand, do any or all of the following:

          (a) declare all Obligations immediately due and payable (but if an
Event of Default described in Section 8.5 occurs all Obligations are immediately
due and payable without any action by Bank);

          (b) stop advancing money or extending credit for Borrower's benefit
under this Agreement or under any other agreement between Borrower and Bank;

          (c) demand that Borrower (i) deposits cash with Bank in an amount
equal to the aggregate amount of any Letters of Credit remaining undrawn, as
collateral security for the repayment of any future drawings under such Letters
of Credit, and Borrower shall forthwith deposit and pay such amounts, and (ii)
pay in advance all Letter of Credit fees scheduled to be paid or payable over
the remaining term of any Letters of Credit;

          (d) [intentionally omitted];

          (e) settle or adjust disputes and claims directly with Account Debtors
for amounts on terms and in any order that Bank considers advisable, notify any
Person owing Borrower money of Bank's security interest in such funds, and
verify the amount of such account;

                                      -16-

<PAGE>

          (f) make any payments and do any acts it considers necessary or
reasonable to protect the Collateral and/or its security interest in the
Collateral. Borrower shall assemble the Collateral if Bank requests and make it
available as Bank designates. Bank may enter premises where the Collateral is
located, take and maintain possession of any part of the Collateral, and pay,
purchase, contest, or compromise any Lien which appears to be prior or superior
to its security interest and pay all expenses incurred. Borrower grants Bank a
license to enter and occupy any of its premises, without charge, to exercise any
of Bank's rights or remedies;

          (g) apply to the Obligations any (i) balances and deposits of Borrower
it holds, or (ii) any amount held by Bank owing to or for the credit or the
account of Borrower;

          (h) ship, reclaim, recover, store, finish, maintain, repair, prepare
for sale, advertise for sale, and sell the Collateral. Bank is hereby granted a
non-exclusive, royalty-free license or other right to use, without charge,
Borrower's labels, patents, copyrights, mask works, rights of use of any name,
trade secrets, trade names, trademarks, service marks, and advertising matter,
or any similar property as it pertains to the Collateral, in completing
production of, advertising for sale, and selling any Collateral and, in
connection with Bank's exercise of its rights under this Section, Borrower's
rights under all licenses and all franchise agreements inure to Bank's benefit;

          (i) place a "hold" on any account maintained with Bank and/or deliver
a notice of exclusive control, any entitlement order, or other directions or
instructions pursuant to any Control Agreement or similar agreements providing
control of any Collateral;

          (j) demand and receive possession of Borrower's Books; and

          (k) exercise all rights and remedies available to Bank under the Loan
Documents or at law or equity, including all remedies provided under the Code
(including disposal of the Collateral pursuant to the terms thereof).

     9.2 POWER OF ATTORNEY. Borrower hereby irrevocably appoints Bank as its
lawful attorney-in-fact, exercisable upon the occurrence and during the
continuance of an Event of Default, to: (a) endorse Borrower's name on any
checks or other forms of payment or security; (b) sign Borrower's name on any
invoice or bill of lading for any Account or drafts against Account Debtors; (c)
settle and adjust disputes and claims about the Accounts directly with Account
Debtors, for amounts and on terms Bank determines reasonable; (d) make, settle,
and adjust all claims under Borrower's insurance policies; (e) pay, contest or
settle any Lien, charge, encumbrance, security interest, and adverse claim in or
to the Collateral, or any judgment based thereon, or otherwise take any action
to terminate or discharge the same; and (f) transfer the Collateral into the
name of Bank or a third party as the Code permits. Borrower hereby appoints Bank
as its lawful attorney-in-fact to sign Borrower's name on any documents
necessary to perfect or continue the perfection of any security interest
regardless of whether an Event of Default has occurred until all Obligations
have been satisfied in full and Bank is under no further obligation to make
Credit Extensions hereunder. Bank's foregoing appointment as Borrower's attorney
in fact, and all of Bank's rights and powers, coupled with an interest, are
irrevocable until all Obligations have been fully repaid and performed and
Bank's obligation to provide Credit Extensions terminates.

     9.3 PROTECTIVE PAYMENTS. If Borrower fails to obtain the insurance called
for by Section 6.7 or fails to pay any premium thereon or fails to pay any other
amount which Borrower is obligated to pay under this Agreement or any other Loan
Document, Bank may obtain such insurance or make such payment, and all amounts
so paid by Bank are Bank Expenses and immediately due and payable, bearing
interest at the then highest applicable rate, and secured by the Collateral.
Bank will make reasonable efforts to provide Borrower with notice of Bank
obtaining such insurance at the time it is obtained or within a reasonable time
thereafter. No payments by Bank are deemed an agreement to make similar payments
in the future or Bank's waiver of any Event of Default.

     9.4 APPLICATION OF PAYMENTS AND PROCEEDS. Unless an Event of Default has
occurred and is continuing, Bank shall apply any funds in its possession,
whether from Borrower account balances, payments, or proceeds realized as the
result of any collection of Accounts or other disposition of the Collateral,
first, to Bank Expenses then due, including without limitation, the reasonable
costs, expenses, liabilities, obligations and attorneys' fees incurred by Bank
in the exercise of its rights under this Agreement; second, to the interest due
upon any of the Obligations; and third, to the principal of the Obligations and
any applicable fees and other charges then

                                      -17-

<PAGE>

due, in such order as Bank shall determine in its sole discretion. Any surplus
shall be paid to Borrower or other Persons legally entitled thereto; Borrower
shall remain liable to Bank for any deficiency. If an Event of Default has
occurred and is continuing, Bank may apply any funds in its possession, whether
from Borrower account balances, payments, proceeds realized as the result of any
collection of Accounts or other disposition of the Collateral, or otherwise, to
the Obligations in such order as Bank shall determine in its sole discretion.
Any surplus shall be paid to Borrower or other Persons legally entitled thereto;
Borrower shall remain liable to Bank for any deficiency. If Bank, in its good
faith business judgment, directly or indirectly enters into a deferred payment
or other credit transaction with any purchaser at any sale of Collateral, Bank
shall have the option, exercisable at any time, of either reducing the
Obligations by the principal amount of the purchase price or deferring the
reduction of the Obligations until the actual receipt by Bank of cash therefor.

     9.5 BANK'S LIABILITY FOR COLLATERAL. So long as Bank complies with
reasonable banking practices regarding the safekeeping of the Collateral in the
possession or under the control of Bank, Bank shall not be liable or responsible
for: (a) the safekeeping of the Collateral; (b) any loss or damage to the
Collateral; (c) any diminution in the value of the Collateral; or (d) any act or
default of any carrier, warehouseman, bailee, or other Person. Borrower bears
all risk of loss, damage or destruction of the Collateral.

     9.6 NO WAIVER; REMEDIES CUMULATIVE. Bank's failure, at any time or times,
to require strict performance by Borrower of any provision of this Agreement or
any other Loan Document shall not waive, affect, or diminish any right of Bank
thereafter to demand strict performance and compliance herewith or therewith. No
waiver hereunder shall be effective unless signed by Bank and then is only
effective for the specific instance and purpose for which it is given. Bank's
rights and remedies under this Agreement and the other Loan Documents are
cumulative. Bank has all rights and remedies provided under the Code, by law, or
in equity. Bank's exercise of one right or remedy is not an election, and Bank's
waiver of any Event of Default is not a continuing waiver. Bank's delay in
exercising any remedy is not a waiver, election, or acquiescence.

     9.7 DEMAND WAIVER. Except if and to the extent expressly otherwise provided
herein or in any other Loan Document, Borrower waives demand, notice of default
or dishonor, notice of payment and nonpayment, notice of any default, nonpayment
at maturity, release, compromise, settlement, extension, or renewal of accounts,
documents, instruments, chattel paper, and guarantees held by Bank on which
Borrower is liable.

     10 NOTICES

     All notices, consents, requests, approvals, demands, or other communication
(collectively, "COMMUNICATION"), other than Advance requests made pursuant to
Section 3.4, by any party to this Agreement or any other Loan Document must be
in writing and be delivered or sent by facsimile at the addresses or facsimile
numbers listed below. Each such Communication shall be deemed to have been
validly served, given, or delivered: (a) upon the earlier of actual receipt and
three (3) Business Days after deposit in the U.S. mail, registered or certified
mail, return receipt requested, with proper postage prepaid; (b) upon
transmission, when sent by facsimile transmission (with such facsimile promptly
confirmed by delivery of a copy by personal delivery or United States mail as
otherwise provided in this Section 10); (c) one (1) Business Day after deposit
with a reputable overnight courier with all charges prepaid; or (d) when
delivered, if hand-delivered by messenger, all of which shall be addressed to
the party to be notified and sent to the address or facsimile number indicated
below. Advance requests made pursuant to Section 3.4 must be confirmed in
writing and may be in the form of electronic mail, delivered to Bank by Borrower
at the e-mail address of Bank provided below and shall be deemed to have been
validly served, given, or delivered when sent (with such electronic mail
promptly confirmed by delivery of a copy by personal delivery or United States
mail as otherwise provided in this Section 10). Bank or Borrower may change its
notice address, facsimile number, or electronic mail address by giving the other
party written notice thereof in accordance with the terms of this Section 10.
All notices to Borrower shall be sent, as provided herein, in care of Endocare
with respect to any and all Borrowers.

                                      -18-

<PAGE>

     If to Borrower: c/o Endocare, Inc.
                     201 Technology Drive
                     Irvine, California 92618
                     Attn: Michael Rodriguez, CFO
                     Fax: 949.450.5309
                     Email: mrodriguez@endocare.com

     If to Bank:     Silicon Valley Bank
                     38 Technology Drive
                     Irvine, California 92618
                     Attn: Kurt Miklinski, VP
                     Fax: 949.789.1930
                     Email: kmiklins@svbank.com

     11 CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER

     California law governs the Loan Documents without regard to principles of
conflicts of law. Borrower and Bank each submit to the exclusive jurisdiction of
the State and Federal courts in Santa Clara County, California; provided,
however, that nothing in this Agreement shall be deemed to operate to preclude
Bank from bringing suit or taking other legal action in any other jurisdiction
to realize on the Collateral or any other security for the Obligations, or to
enforce a judgment or other court order in favor of Bank. Borrower expressly
submits and consents in advance to such jurisdiction in any action or suit
commenced in any such court, and Borrower hereby waives any objection that it
may have based upon lack of personal jurisdiction, improper venue, or forum non
conveniens and hereby consents to the granting of such legal or equitable relief
as is deemed appropriate by such court. Borrower hereby waives personal service
of the summons, complaints, and other process issued in such action or suit and
agrees that service of such summons, complaints, and other process may be made
by registered or certified mail addressed to Borrower at the address set forth
in Section 10 of this Agreement and that service so made shall be deemed
completed upon the earlier to occur of Borrower's actual receipt thereof or
three (3) Business Days after deposit in the U.S. mails, proper postage prepaid.

BORROWER AND BANK EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE
OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY
CONTEMPLATED TRANSACTION HEREUNDER OR THEREUNDER, INCLUDING CONTRACT, TORT,
BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR
BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER
WITH ITS COUNSEL.

     12 GENERAL PROVISIONS

     12.1 SUCCESSORS AND ASSIGNS. This Agreement binds and is for the benefit of
the successors and permitted assigns of each party. Borrower may not assign this
Agreement or any rights or obligations under it without Bank's prior written
consent (which may be granted or withheld in Bank's discretion). Bank has the
right, without the consent of or notice to Borrower, to sell, transfer,
negotiate, or grant participation in all or any part of, or any interest in,
Bank's obligations, rights, and benefits under this Agreement and the other Loan
Documents.

     12.2 INDEMNIFICATION. Borrower agrees to indemnify, defend and hold Bank
and its directors, officers, employees, agents, attorneys, or any other Person
affiliated with or representing Bank harmless against: (a) all obligations,
demands, claims, and liabilities (collectively, "Claims") asserted by any other
party in connection with the transactions contemplated by the Loan Documents;
and (b) all losses or Bank Expenses incurred, or paid by Bank from, following,
or arising from transactions between Bank and Borrower in connection with the
Loan Documents (including reasonable attorneys' fees and expenses), except for
Claims and/or losses directly caused by Bank's gross negligence or willful
misconduct. This Section 12.2 shall survive any termination of this Agreement or
any other Loan Document.

     12.3 LIMITATION OF ACTIONS. Any claim or cause of action by Borrower
against Bank, its directors, officers, employees, agents, accountants,
attorneys, or any other Person affiliated with or representing Bank based upon,
arising from, or relating to this Agreement or any other Loan Document, or any
other transaction

                                      -19-

<PAGE>

contemplated hereby or thereby or relating hereto or thereto, or any other
matter, cause or thing whatsoever, occurred, done, omitted or suffered to be
done by Bank, its directors, officers, employees, agents, accountants or
attorneys, relating hereto or thereto, shall be barred unless asserted by
Borrower by the commencement of an action or proceeding in a court of competent
jurisdiction by the filing of a complaint within two years after the first act,
occurrence or omission upon which such claim or cause of action, or any part
thereof, is based, and the service of a summons and complaint on an officer of
Bank, or on any other person authorized to accept service on behalf of Bank,
within thirty (30) days thereafter. Borrower agrees that such two-year period is
a reasonable and sufficient time for Borrower to investigate and act upon any
such claim or cause of action. The two-year period provided herein shall not be
waived, tolled, or extended except by the written consent of Bank in its sole
discretion. This provision shall survive any termination of this Agreement or
any other Loan Document.

     12.4 TIME OF ESSENCE. Time is of the essence for the performance of all
Obligations in this Agreement.

     12.5 SEVERABILITY OF PROVISIONS. Each provision of this Agreement is
severable from every other provision in determining the enforceability of any
provision.

     12.6 AMENDMENTS IN WRITING; INTEGRATION. All amendments to this Agreement
must be in writing signed by both Bank and Borrower. This Agreement and the Loan
Documents represent the entire agreement about this subject matter and supersede
prior negotiations or agreements. All prior agreements, understandings,
representations, warranties, and negotiations between the parties about the
subject matter of this Agreement and the Loan Documents merge into this
Agreement and the Loan Documents.

     12.7 COUNTERPARTS. This Agreement may be executed in any number of
counterparts and by different parties on separate counterparts, each of which,
when executed and delivered, are an original, and all taken together, constitute
one Agreement.

     12.8 SURVIVAL. All covenants, representations and warranties made in this
Agreement continue in full force until this Agreement has terminated pursuant to
its terms and all Obligations (other than inchoate indemnity obligations and any
other obligations which, by their terms, are to survive the termination of this
Agreement) have been satisfied. The obligation of Borrower in Section 12.2 to
indemnify Bank shall survive until the statute of limitations with respect to
such claim or cause of action shall have run.

     12.9 CONFIDENTIALITY. In handling any confidential information, Bank shall
exercise the same degree of care that it exercises for its own proprietary
information, but disclosure of information may be made: (a) to Bank's
Subsidiaries or Affiliates in connection with their business relating to
Borrower; (b) to prospective transferees or purchasers of any interest in the
Credit Extensions (provided, however, Bank shall use commercially reasonable
efforts to obtain such prospective transferee's or purchaser's agreement to the
terms of this provision); (c) as required by law, regulation, subpoena, or other
order; (d) to Bank's regulators or as otherwise required in connection with
Bank's examination or audit; and (e) as Bank considers appropriate in exercising
remedies under this Agreement and the other Loan Documents. Confidential
information does not include information that either: (i) is in the public
domain or in Bank's possession when disclosed to Bank, or becomes part of the
public domain after disclosure to Bank; or (ii) is disclosed to Bank by a third
party, if Bank does not know that the third party is prohibited from disclosing
the information.

     12.10 ATTORNEYS' FEES, COSTS AND EXPENSES. In any action or proceeding
between Borrower and Bank arising out of or relating to the Loan Documents, the
prevailing party shall be entitled to recover its reasonable attorneys' fees and
other costs and expenses incurred, in addition to any other relief to which it
may be entitled.

     13 DEFINITIONS

     13.1 DEFINITIONS. As used in this Agreement, the following terms have the
following meanings:

     "ACCOUNT" is any "account" as defined in the Code with such additions to
such term as may hereafter be made, and includes, without limitation, all
accounts receivable and other sums owing to Borrower.

                                      -20-

<PAGE>

     "ACCOUNT DEBTOR" is any "account debtor" as defined in the Code with such
additions to such term as may hereafter be made.

     "ADVANCE" or "ADVANCES" means an advance (or advances) under the Revolving
Line.

     "AFFILIATE" of any Person is a Person that owns or controls directly or
indirectly the Person, any Person that controls or is controlled by or is under
common control with the Person, and each of that Person's senior executive
officers, directors, partners and, for any Person that is a limited liability
company, that Person's managers and members.

     "AGREEMENT" is defined in the preamble hereof.

     "BANK" is defined in the preamble hereof.

     "BANK EXPENSES" are all audit fees and expenses, costs, and expenses
(including reasonable attorneys' fees and expenses) for preparing, negotiating,
administering, defending and enforcing the Loan Documents (including, without
limitation, those incurred in connection with appeals or Insolvency Proceedings)
or otherwise incurred with respect to Borrower.

     "BORROWER" is defined in the preamble hereof

     "BORROWER'S BOOKS" are all Borrower's books and records including ledgers,
federal and state tax returns, records regarding Borrower's assets or
liabilities, the Collateral, business operations or financial condition, and all
computer programs or storage or any equipment containing such information.

     "BORROWING BASE" is (a) 80% of Eligible Accounts plus (b) the lesser of 30%
of the value of Borrower's Eligible Inventory (valued at the lower of cost or
wholesale fair market value) or $500,000, as determined by Bank from Borrower's
most recent Borrowing Base Certificate; provided, however, that Bank may
decrease the foregoing percentages in its good faith business judgment based on
events, conditions, contingencies, or risks which, as determined by Bank, may
adversely affect Collateral.

     "BORROWING BASE CERTIFICATE" is a borrowing base certificate in form and
substance satisfactory to Bank.

     "BORROWING RESOLUTIONS" are, with respect to any Person, those resolutions
adopted by such Person's Board of Directors and delivered by such Person to Bank
approving the Loan Documents to which such Person is a party and the
transactions contemplated thereby, together with a certificate executed by its
secretary on behalf of such Person certifying that (a) such Person has the
authority to execute, deliver, and perform its obligations under each of the
Loan Documents to which it is a party, (b) that attached as Exhibit A to such
certificate is a true, correct, and complete copy of the resolutions then in
full force and effect authorizing and ratifying the execution, delivery, and
performance by such Person of the Loan Documents to which it is a party, (c) the
name(s) of the Person(s) authorized to execute the Loan Documents on behalf of
such Person, together with a sample of the true signature(s) of such Person(s),
and (d) that Bank may conclusively rely on such certificate unless and until
such Person shall have delivered to Bank a further certificate canceling or
amending such prior certificate.

     "BUSINESS DAY" is any day that is not a Saturday, Sunday or a day on which
Bank is closed.

     "CASH EQUIVALENTS" means (a) marketable direct obligations issued or
unconditionally guaranteed by the United States or any agency or any State
thereof having maturities of not more than one (1) year from the date of
acquisition; (b) commercial paper maturing no more than one (1) year after its
creation and having the highest rating from either Standard & Poor's Ratings
Group or Moody's Investors Service, Inc., (c) Bank's certificates of deposit
issued maturing no more than one (1) year after issue; and (d) money market
funds at least ninety-five percent (95%) of the assets of which constitute Cash
Equivalents of the kinds described in clauses (a) through (c) of this
definition.

     "CHANGE IN CONTROL" means any event, transaction, or occurrence as a result
of which any one or more of the following occurs: (a) any "person" (as such term
is defined in Sections 3(a)(9) and 13(d)(3) of the Securities Exchange Act of
1934, as an amended (the "EXCHANGE ACT")), other than a trustee or other
fiduciary holding securities under an employee benefit plan of Endocare, is or
becomes a beneficial owner (within the meaning Rule

                                      -21-
<PAGE>

13d-3 promulgated under the Exchange Act), directly or indirectly, of securities
of Endocare, representing twenty-five percent (25%) or more of the combined
voting power of Endocare's then outstanding securities; or (b) during any period
of twelve consecutive calendar months, individuals who at the beginning of such
period constituted the Board of Directors of Endocare (together with any new
directors whose election by the Board of Directors of Endocare was approved by a
vote of at least two-thirds of the directors then still in office who either
were directions at the beginning of such period or whose election or nomination
for election was previously so approved) cease for any reason other than death
or disability to constitute a majority of the directors then in office; or (c)
Endocare ceases to own and control 100% of the issued and outstanding capital
stock of each other Borrower.

     "CODE" is the Uniform Commercial Code, as the same may, from time to time,
be enacted and in effect in the State of California; provided, that, to the
extent that the Code is used to define any term herein or in any Loan Document
and such term is defined differently in different Articles or Divisions of the
Code, the definition of such term contained in Article or Division 9 shall
govern; provided further, that in the event that, by reason of mandatory
provisions of law, any or all of the attachment, perfection, or priority of, or
remedies with respect to, Bank's Lien on any Collateral is governed by the
Uniform Commercial Code in effect in a jurisdiction other than the State of
California, the term "CODE" shall mean the Uniform Commercial Code as enacted
and in effect in such other jurisdiction solely for purposes on the provisions
thereof relating to such attachment, perfection, priority, or remedies and for
purposes of definitions relating to such provisions.

     "COLLATERAL" is any and all properties, rights and assets of Borrower
described on Exhibit A.

     "COLLATERAL ACCOUNT" is any Deposit Account, Securities Account, or
Commodity Account.

     "COMMODITY ACCOUNT" is any "commodity account" as defined in the Code with
such additions to such term as may hereafter be made.

     "COMMUNICATION" is defined in Section 10.

     "COMPLIANCE CERTIFICATE" is that certain certificate in the form attached
hereto as Exhibit E.

     "CONTINGENT OBLIGATION" is, for any Person, any direct or indirect
liability, contingent or not, of that Person for (a) any indebtedness, lease,
dividend, letter of credit or other obligation of another such as an obligation
directly or indirectly guaranteed, endorsed, co-made, discounted or sold with
recourse by that Person, or for which that Person is directly or indirectly
liable; (b) any obligations for undrawn letters of credit for the account of
that Person; and (c) all obligations from any interest rate, currency or
commodity swap agreement, interest rate cap or collar agreement, or other
agreement or arrangement designated to protect a Person against fluctuation in
interest rates, currency exchange rates or commodity prices; but "Contingent
Obligation" does not include endorsements in the ordinary course of business.
The amount of a Contingent Obligation is the stated or determined amount of the
primary obligation for which the Contingent Obligation is made or, if not
determinable, the maximum reasonably anticipated liability for it determined by
the Person in good faith; but the amount may not exceed the maximum of the
obligations under any guarantee or other support arrangement.

     "CONTROL AGREEMENT" is any control agreement entered into among the
depository institution at which Borrower maintains a Deposit Account or the
securities intermediary or commodity intermediary at which Borrower maintains a
Securities Account or a Commodity account, Borrower, and Bank pursuant to which
Bank obtains control (within the meaning of the Code) over such Deposit Account,
Securities Account, or Commodity Account.

     "CREDIT EXTENSION" is any Advance or any other extension of credit by Bank
for Borrower's benefit.

     "CROSS-GUARANTY" is that certain Cross-Corporate Continuing Guaranty, dated
on or about the Effective Date, executed and delivered by each Borrower in favor
of Bank relative to each other Borrower.

     "CURRENT LIABILITIES" are the aggregate amount of Endocare's consolidated
Total Liabilities (including, without duplication, all obligations and
liabilities of Borrower to Bank) that mature within one (1) year.

     "DEFAULT" means any event which with notice or passage of time or both,
would constitute an Event of Default.

                                      -22-

<PAGE>

     "DEFAULT RATE" is defined in Section 2.3(b).

     "DEFERRED REVENUE" is all amounts received or invoiced in advance of
performance under contracts and not yet recognized as revenue.

     "DEPOSIT ACCOUNT" is any "deposit account" as defined in the Code with such
additions to such term as may hereafter be made.

     "DESIGNATED DEPOSIT ACCOUNT" is Borrower's deposit account, account number
0600801170, maintained with Bank.

     "DOLLARS," "DOLLARS" and "$" each mean lawful money of the United States.

     "EFFECTIVE DATE" is the date Bank executes this Agreement and as indicated
on the signature page hereof.

     "ELIGIBLE ACCOUNTS" are Accounts which arise, and have been billed, in the
ordinary course of Borrower's business and that meet all of Borrower's
representations and warranties in Section 5.3. Bank reserves the right, by
giving prior notice to Borrower, at any time and from time to time after the
Effective Date, to adjust any of the criteria set forth below and to establish
new criteria in its good faith business judgment (collectively, the "MINIMUM
ELIGIBILITY REQUIREMENTS"). Unless Bank agrees otherwise in writing, Eligible
Accounts shall not include:

     (a) Accounts that the Account Debtor has not paid within ninety (90) days
of invoice date;

     (b) Accounts owing from an Account Debtor, fifty percent (50%) or more of
whose Accounts have not been paid within ninety (90) days of invoice date;

     (c) Credit balances over ninety (90) days from invoice date;

     (d) Accounts owing from an Account Debtor, including Affiliates, whose
total obligations to Borrower exceed twenty-five (25%) of all Accounts, for the
amounts that exceed that percentage, unless Bank approves in writing;

     (e) Accounts owing from an Account Debtor which does not have its principal
place of business in the United States (unless pre-approved by Bank in its
discretion in writing, or backed by a letter of credit satisfactory to Bank, or
FCIA insured satisfactory to Bank);

     (f) Accounts owing from the United States or any department, agency or
instrumentality thereof (unless there has been compliance, to Bank's
satisfaction, with the United States Assignment of Claims Act);

     (g) Accounts owing from an Account Debtor to the extent that Borrower is
indebted or obligated in any manner to the Account Debtor (as creditor, lessor,
supplier or otherwise - sometimes called "contra" accounts, accounts payable,
customer deposits or credit accounts), with the exception of customary credits,
adjustments and/or discounts given to an Account Debtor by Borrower in the
ordinary course of its business;

     (h) Accounts for demonstration or promotional equipment, or in which goods
are consigned, or sold on a "sale guaranteed", "sale or return", "sale on
approval", "bill and hold", or other terms if Account Debtor's payment may be
conditional;

     (i) Accounts for which the Account Debtor is Borrower's Affiliate, officer,
employee, or agent;

     (j) Accounts in which the Account Debtor disputes liability or makes any
claim (but only up to the disputed or claimed amount), or if the Account Debtor
is subject to an Insolvency Proceeding, or becomes insolvent, or goes out of
business;

     (k) Accounts owing from an Account Debtor with respect to which Borrower
has received deferred revenue (but only to the extent of such deferred revenue);

                                      -23-

<PAGE>

     (l) Accounts for which Bank in its good faith business judgment determines
collection to be doubtful;

     (m) Accounts that arise from the sale, lease, licensing, assignment, or
other disposition of any copyright, maskwork, or other work of authorship of
Borrower that is registered (or the subject of an application for registration)
with the United States Copyright Office (a "Registered Copyright"), unless
Borrower is in full compliance with Section 6.10 with respect to such Account
and such Registered Copyright;

     and

     (n) other Accounts Bank deems ineligible in the exercise of its good faith
business judgment.

     "ELIGIBLE INVENTORY" means, at any time, the aggregate of Borrower's
Inventory that: (a) consists of raw materials and finished goods, in good, new,
and salable condition, which is not perishable, returned, consigned, obsolete,
not sellable, damaged, or defective, and is not comprised of demonstrative or
custom inventory, works in progress, packaging or shipping materials, or
supplies; (b) meets all applicable governmental standards; (c) has been
manufactured in compliance with the Fair Labor Standards Act; (d) is not subject
to any Liens, except the first priority Liens granted in favor of Bank under
this Agreement or any of the other Loan Documents (subject in lien priority only
to those Permitted Liens that are expressly entitled to such priority over the
security interests of Bank by operation of law or by written subordination
agreement duly executed and delivered by Bank in favor of the holders of such
Permitted Liens); (e) is located at Endocare's principal place of business, 201
Technology Drive, Irvine, California 92618; and (f) is otherwise acceptable to
Bank in its good faith business judgment.

     "ENDOCARE" is defined in the preamble of this Agreement.

     "EQUIPMENT" is all "equipment" as defined in the Code with such additions
to such term as may hereafter be made, and includes without limitation all
machinery, fixtures, goods, vehicles (including motor vehicles and trailers),
and any interest in any of the foregoing.

     "ERISA" is the Employment Retirement Income Security Act of 1974, and its
regulations.

     "EVENT OF DEFAULT" is defined in Section 8.

     "FUNDING DATE" is any date on which a Credit Extension is made to or on
account of Borrower which shall be a Business Day.

     "GAAP" is generally accepted accounting principles set forth in the
opinions and pronouncements of the Accounting Principles Board of the American
Institute of Certified Public Accountants and statements and pronouncements of
the Financial Accounting Standards Board or in such other statements by such
other Person as may be approved by a significant segment of the accounting
profession, which are applicable to the circumstances as of the date of
determination.

     "GENERAL INTANGIBLES" is all "general intangibles" as defined in the Code
in effect on the date hereof with such additions to such term as may hereafter
be made, and includes without limitation, all copyright rights, copyright
applications, copyright registrations and like protections in each work of
authorship and derivative work, whether published or unpublished, any patents,
trademarks, service marks and, to the extent permitted under applicable law, any
applications therefor, whether registered or not, any trade secret rights,
including any rights to unpatented inventions, payment intangibles, royalties,
contract rights, goodwill, franchise agreements, purchase orders, customer
lists, route lists, telephone numbers, domain names, claims, income and other
tax refunds, security and other deposits, options to purchase or sell real or
personal property, rights in all litigation presently or hereafter pending
(whether in contract, tort or otherwise), insurance policies (including without
limitation key man, property damage, and business interruption insurance),
payments of insurance and rights to payment of any kind.

     "GUARANTOR" is any present or future guarantor of the Obligations.

     "INACTIVE SUBSIDIARIES" has the meaning ascribed to such term in Section
5.1A.

                                      -24-

<PAGE>

     "INDEBTEDNESS" is (a) indebtedness for borrowed money or the deferred price
of property or services, such as reimbursement and other obligations for surety
bonds and letters of credit, (b) obligations evidenced by notes, bonds,
debentures or similar instruments, (c) capital lease obligations, and (d)
Contingent Obligations.

     "INSOLVENCY PROCEEDING" is any proceeding by or against any Person under
the United States Bankruptcy Code, or any other bankruptcy or insolvency law,
including assignments for the benefit of creditors, compositions, extensions
generally with its creditors, or proceedings seeking reorganization,
arrangement, or other relief.

     "INTELLECTUAL PROPERTY" means all present and future (a) copyrights,
copyright rights, copyright applications, copyright registrations and like
protections in each work of authorship and derivative work thereof, whether
published or unpublished, (b) trade secret rights, including all rights to
unpatented inventions and know how, and confidential information; (c) mask work
or similar rights available for the protection of semiconductor chips; (d)
patents, patent applications and like protections including without limitation
improvements, divisions, continuations, renewals, reissues, extensions and
continuations-in-part of the same (individually and collectively, "PATENT"); (e)
trademarks, servicemarks, trade styles, and trade names, whether or not any of
the foregoing are registered, and all applications to register and registrations
of the same and like protections, and the entire goodwill of the business of
Borrower connected with and symbolized by any such trademarks; (f) computer
software and computer software products; (g) designs and design rights; (h)
technology; (i) all claims for damages by way of past, present and future
infringement of any of the rights included above; (j) all licenses or other
rights to use any property or rights of a type described above.

     "INVENTORY" is all "inventory" as defined in the Code in effect on the date
hereof with such additions to such term as may hereafter be made, and includes
without limitation all merchandise, raw materials, parts, supplies, packing and
shipping materials, work in process and finished products, including without
limitation such inventory as is temporarily out of Borrower's custody or
possession or in transit and including any returned goods and any documents of
title representing any of the above.

     "INVESTMENT" is any beneficial ownership interest in any Person (including
stock, partnership interest or other securities), and any loan, advance or
capital contribution to any Person.

     "IP SECURITY AGREEMENT" is that certain Intellectual Property Security
Agreement executed and delivered by Borrower to Bank dated as of the Effective
Date.

     "LIEN" is a mortgage, lien, deed of trust, charge, pledge, security
interest or other encumbrance.

     "LOAN DOCUMENTS" are, collectively, this Agreement, the Perfection
Certificate, the IP Security Agreement, any note, or notes or guaranties
executed by Borrower or any Guarantor, and any other present or future agreement
between Borrower or any Guarantor, on the one hand, and/or for the benefit of
Bank, on the other hand, in connection with this Agreement, all as amended,
restated, or otherwise modified.

     "LOAN MARGIN" has the meaning ascribed to such term in Section 2.3(a).

     "MATERIAL ADVERSE CHANGE" is (a) a material impairment in the perfection or
priority of Bank's Lien in the Collateral or in the value of such Collateral;
(b) a material adverse change in the business, operations, or condition
(financial or otherwise) of Endocare and its Subsidiaries, taken as a whole; (c)
a material impairment of the prospect of repayment of any portion of the
Obligations; or (d) Bank determines, based upon information available to it and
in its good faith reasonable judgment, that there is a reasonable likelihood
that Borrower shall fail to comply with one or more of the financial covenants
in Section 6 during the next succeeding financial reporting period.

     "MATURITY DATE" is the earliest of (a) the date 364 days following the
Effective Date, or (b) if Bank so elects in its good faith business judgment,
the occurrence and continuation of any Event of Default.

     "MAXIMUM REVOLVER AMOUNT" means $4,000,000.

     "MINIMUM ELIGIBILITY REQUIREMENTS" has the meaning ascribed to such term
within the definition of "Eligible Accounts".

                                      -25-

<PAGE>

     "NET INCOME" means, as calculated on a consolidated basis for Endocare and
its Subsidiaries for any period as at any date of determination, the net profit
(or loss), after provision for taxes, of Endocare and its Subsidiaries for such
period taken as a single accounting period.

     "OBLIGATIONS" are Borrower's obligation to pay when due any debts,
principal, interest, Bank Expenses and other amounts Borrower owes Bank now or
later, whether under this Agreement, the Loan Documents, or otherwise,
including, without limitation, all obligations relating to letters of credit,
cash management services, and foreign exchange contracts, if any, and including
interest, and other amounts, accruing after Insolvency Proceedings begin and
debts, liabilities, or obligations of Borrower assigned to Bank, and the
performance of Borrower's duties under the Loan Documents. It is expressly
acknowledged and agreed that each and all of the Borrowers are, and at all times
shall be, jointly and severally liable for all Obligations, regardless of which
Borrower or Borrowers requested, received, used, or directly enjoyed the benefit
of, the Obligations.

     "OPERATING DOCUMENTS" are, for any Person, such Person's formation
documents, as certified with the Secretary of State of such Person's state of
formation on a date that is no earlier than 30 days prior to the Effective Date,
and, (a) if such Person is a corporation, its bylaws in current form, (b) if
such Person is a limited liability company, its limited liability company
agreement (or similar agreement), and (c) if such Person is a partnership, its
partnership agreement (or similar agreement), each of the foregoing with all
current amendments or modifications thereto.

     "PATENT" has the meaning ascribed to such term in within the definition of
"Intellectual Property".

     "PAYMENT" means all checks, wire transfers and other items of payment
received by Bank (including proceeds of Accounts and payment of the Obligations
in full) for credit to Borrower's outstanding Credit Extensions or, if the
balance of the Credit Extensions have been reduced to zero, for credit to its
Deposit Accounts.

     "PERFECTION CERTIFICATE" is defined in Section 5.1.

     "PERMITTED EXCLUSIVE LICENSING TRANSACTIONS" means, individually and
collectively, one or more exclusive licenses granted by Borrower, in the
ordinary course of business, pursuant to which Borrower and one or more
third-party co-developers develop technology based on certain core proprietary
Intellectual Property of Borrower, and exploit such co-developed technology;
provided, however that no Permitted Exclusive Licensing Transaction shall effect
or result in: (a) (i) a "transfer of copyright ownership" (within the meaning of
17 U.S.C. Section 101, as amended) with respect to any material portion, or any
significant economic value, of Borrower's core proprietary Intellectual Property
relating to copyrights, maskworks, and other works of authorship, or (ii) the
functional equivalent of the immediately preceding clause (i) as applied to
Borrower's Patent-related Intellectual Property; or (b) a transfer of any
non-immaterial amount of cash of Borrower (other than the sharing between
Borrower and such third-party co-developers of revenue from the exploitation of
such co-developed technology in the ordinary course of business).

     "PERMITTED INDEBTEDNESS" is:

     (a) Borrower's Indebtedness to Bank under this Agreement and the other Loan
Documents;

     (b) Indebtedness existing on the Effective Date and shown on the Perfection
Certificate;

     (c) unsecured Subordinated Debt;

     (d) unsecured Indebtedness to trade creditors incurred in the ordinary
course of business;

     (e) Indebtedness incurred as a result of endorsing negotiable instruments
received in the ordinary course of business;

     (f) Indebtedness, in an aggregate principal amount not to exceed $100,000,
secured by Permitted Liens described in clause (c) of the definition of
"Permitted Liens";

                                      -26-

<PAGE>

     (g) unsecured intercompany Indebtedness among the Borrowers or among
Borrower and its Subsidiaries, in an aggregate amount not to exceed $100,000 at
any one time outstanding; and

     (h) extensions, refinancings, modifications, amendments and restatements of
any items of Permitted Indebtedness (a) through (f) above, provided that the
principal amount thereof is not increased or the terms thereof are not modified
to impose more burdensome terms upon Borrower or its Subsidiary, as the case may
be.

     "PERMITTED INVESTMENTS" are:

     (a) Investments shown on the Perfection Certificate and existing on the
Effective Date;

     (b) (i) Cash Equivalents, and (ii) any Investments permitted by Borrower's
investment policy, as amended from time to time, provided that such investment
policy (and any such amendment thereto) has been approved in writing by Bank
(such approval not to be unreasonably withheld);

     (c) Investments consisting of the endorsement of negotiable instruments for
deposit or collection or similar transactions in the ordinary course of
Borrower;

     (d) Investments consisting of deposit accounts in which Bank has a
perfected security interest (to the extent required hereunder);

     (e) (i) Investments accepted in connection with Transfers permitted by
Section 7.1, or (ii) Transfers permitted by Section 7.3 (if and to the extent
such Transfers constitute Investments);

     (f) (i) Investments by one Borrower in another Borrower; (ii) additional
equity Investments by Borrower in Subsidiaries not to exceed $100,000 in the
aggregate in any fiscal year; and (iii) Investments of Subsidiaries (not a
Borrower) made in or to other Subsidiaries or Borrower;

     (g) Investments consisting of (i) travel advances and employee relocation
loans and other employee loans and advances in the ordinary course of business,
and (ii) loans to employees, officers or directors relating to the purchase of
equity securities of Borrower or its Subsidiaries pursuant to employee stock
purchase plans or agreements approved by Borrower's Board of Directors;

     (h) Investments (including debt obligations) received in connection with
the bankruptcy or reorganization of customers or suppliers and in settlement of
delinquent obligations of, and other disputes with, customers or suppliers
arising in the ordinary course of business;

     (i) Investments consisting of notes receivable of, or prepaid royalties and
other credit extensions, to customers and suppliers who are not Affiliates, in
the ordinary course of business; provided that this paragraph (i) shall not
apply to Investments of Borrower in any Subsidiary; and

     (j) joint ventures or strategic alliances in the ordinary course of
Borrower's business consisting of Permitted Exclusive Licensing Transactions,
the non-exclusive licensing of technology, the development of technology or the
providing of technical support, provided that any cash investments by Borrower
do not exceed $250,000 in the aggregate in any fiscal year.

     "PERMITTED LIENS" are:

     (a) Liens existing on the Effective Date and shown on the Perfection
Certificate or arising under this Agreement and the other Loan Documents;

     (b) Liens for taxes, fees, assessments or other government charges or
levies, either not delinquent or being contested in good faith and for which
Borrower maintains adequate reserves on its Books, if they have no priority over
any of Bank's Liens;

     (c) purchase money Liens (i) on Equipment acquired or held by Borrower
incurred for financing the acquisition of the Equipment securing no more than
$100,000 in the aggregate amount outstanding, or (ii) existing

                                      -27-

<PAGE>

on Equipment when acquired, if the Lien is confined to the property and
improvements and the proceeds of the Equipment;

     (d) statutory Liens securing claims or demands of materialmen, mechanics,
carriers, warehousemen, landlords and other Persons imposed without action of
such parties, provided, they have no priority over any of Bank's Lien and the
aggregate amount of such Liens does not at any time exceed $25,000;

     (e) Liens to secure payment of workers' compensation, employment insurance,
old-age pensions, social security and other like obligations incurred in the
ordinary course of business, provided, they have no priority over any of Bank's
Liens and the aggregate amount of the Indebtedness secured by such Liens does
not at any time exceed $25,000;

     (f) Liens incurred in the extension, renewal or refinancing of the
indebtedness secured by Liens described in (a) through (c), but any extension,
renewal or replacement Lien must be limited to the property encumbered by the
existing Lien and the principal amount of the indebtedness may not increase;

     (g) leases or subleases of real property granted in the ordinary course of
business, and leases, subleases, non-exclusive licenses or sublicenses of
property (other than real property or Intellectual Property) granted in the
ordinary course of Borrower's business, if the leases, subleases, licenses and
sublicenses do not prohibit granting Bank a security interest;

     (h) Permitted Exclusive Licensing Transactions and non-exclusive licenses
of Intellectual Property granted to third parties in the ordinary course of
business;

     (i) Liens arising from judgments, decrees or attachments in circumstances
not constituting an Event of Default under Section 8.4 or 8.7; and

     (j) Liens in favor of other financial institutions arising in connection
with Borrower's deposit and/or securities accounts permitted hereunder held at
such institutions, provided that Bank has a perfected security interest in the
amounts held in such deposit and/or securities accounts.

     "PERSON" is any individual, sole proprietorship, partnership, limited
liability company, joint venture, company, trust, unincorporated organization,
association, corporation, institution, public benefit corporation, firm, joint
stock company, estate, entity or government agency.

     "PHASE I" has the meaning ascribed in Section 1A hereof.

     "PHASE I RESET DATE" has the meaning ascribed in Section 1A hereof.

     "PHASE II" has the meaning ascribed in Section 1A hereof.

     "PHASE II TRIGGER DATE" has the meaning ascribed in Section 1A hereof.

     "PRIME RATE" is Bank's most recently announced "prime rate," even if it is
not Bank's lowest rate.

     "QUICK ASSETS" is, on any date, Endocare's and its Subsidiaries'
consolidated unrestricted cash, Cash Equivalents, net billed accounts receivable
and investments with maturities of fewer than 12 months determined according to
GAAP.

     "QUICK RATIO" means, as of any date of determination and with respect to
any Person, the ratio of such Person's Quick Assets to such Person's Current
Liabilities.

     "QUICK RATIO THRESHHOLD" has the meaning ascribed in Section 1A hereof.

     "REGISTERED ORGANIZATION" is any "registered organization" as defined in
the Code with such additions to such term as may hereafter be made

                                      -28-

<PAGE>

     "RESERVES" means, as of any date of determination, such amounts as Bank may
from time to time establish and revise in its good faith business judgment,
reducing the amount of Credit Extensions and other financial accommodations
which would otherwise be available to Borrower under the lending formula(s)
provided in this Agreement: (a) to reflect events, conditions, contingencies or
risks which, as determined by Bank in its good faith business judgment, do or
may adversely affect (i) the Collateral or any other property which is security
for the Obligations or its value (including without limitation any increase in
delinquencies of Accounts), (ii) the assets, business or prospects of Borrower
or any Guarantor, or (iii) the security interests and other rights of Bank in
the Collateral (including the enforceability, perfection and priority thereof);
or (b) to reflect Bank's good faith belief that any collateral report or
financial information furnished by or on behalf of Borrower or any Guarantor to
Bank is or may have been incomplete, inaccurate or misleading in any material
respect; or (c) in respect of any state of facts which Bank determines in good
faith constitutes an Event of Default or may, with notice or passage of time or
both, constitute an Event of Default.

     "RESPONSIBLE OFFICER" is any of the Chief Executive Officer, President,
Chief Financial Officer and Controller of Borrower.

     "REVOLVING LINE" is the revolving line of credit (and sublines thereof, if
any), set forth in Section 2.1.1, pursuant to which one or more Advances (or
other Credit Extensions, if any, pursuant to such sublines), in an aggregate
outstanding amount of up to the Maximum Revolver Amount at any one time, may be
requested by Borrower and made by Bank subject to the terms and conditions of
this Agreement.

     "SECURITIES ACCOUNT" is any "securities account" as defined in the Code
with such additions to such term as may hereafter be made.

     "SUBORDINATED DEBT" is indebtedness incurred by Borrower subordinated to
all of Borrower's now or hereafter indebtedness to Bank (pursuant to a
subordination, intercreditor, or other similar agreement in form and substance
satisfactory to Bank entered into between Bank and the other creditor), on terms
acceptable to Bank.

     "SUBSIDIARY" means, with respect to any Person, any Person of which more
than 50% of the voting stock or other equity interests is owned or controlled,
directly or indirectly, by such Person or one or more Affiliates of such Person.

     "TANGIBLE NET WORTH" is, on any date, the consolidated total assets of
Endocare and its Subsidiaries minus (a) any amounts attributable to (i)
goodwill, (ii) intangible items including unamortized debt discount and expense,
patents, trade and service marks and names, copyrights and research and
development expenses except prepaid expenses, (iii) notes, accounts receivable
and other obligations owing to Borrower from its officers or other Affiliates,
and (iv) reserves not already deducted from assets, minus (b) Total Liabilities.
Solely for purposes of calculating Tangible Net Worth, there shall be excluded
from Total Liabilities any liabilities for Endocare's warrants issued on March
11, 2005.

     "TIMM" is defined in the preamble of this Agreement.

     "TOTAL LIABILITIES" is on any day, obligations that should, under GAAP, be
classified as liabilities on Endocare's consolidated balance sheet, including
all Indebtedness, but excluding all Subordinated Debt.

     "TRANSACTION REPORT" is a Borrowing Base Certificate.

     "TRANSFER" is defined in Section 7.1.

     "UNUSED REVOLVING LINE FACILITY FEE" is defined in Section 2.4(d).

                            [Signature page follows.]

                                      -29-

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the Effective Date.

BORROWER:

ENDOCARE, INC.

By /s/ Michael Rodriguez
   ----------------------------------
Name: Michael Rodriguez
Title: SVP, Finance & CFO

TIMM MEDICAL TECHNOLOGIES, INC.

By /s/ Michael Rodriguez
   ----------------------------------
Name: Michael Rodriguez
Title: CFO

BANK:

SILICON VALLEY BANK

By /s/ Kurt Miklinski
   ----------------------------------
Name: Kurt Miklinski
Title: Vice President

TO BE COMPLETED ONLY BY BANK:

Effective Date: 10/26/05

                 [Signature page to Loan and Security Agreement]

<PAGE>

                                    EXHIBIT A

The Collateral consists of all of Borrower's right, title and interest in and to
the following personal property:

     All goods, Accounts (including health-care receivables), Equipment,
Inventory, contract rights or rights to payment of money, leases, license
agreements, franchise agreements, General Intangibles, commercial tort claims,
documents, instruments (including any promissory notes), chattel paper (whether
tangible or electronic), cash, deposit accounts, fixtures, letters of credit
rights (whether or not the letter of credit is evidenced by a writing),
securities, and all other investment property, supporting obligations, and
financial assets, whether now owned or hereafter acquired, wherever located; and

     all Borrower's Books relating to the foregoing, and any and all claims,
rights and interests in any of the above and all substitutions for, additions,
attachments, accessories, accessions and improvements to and replacements,
products, proceeds and insurance proceeds of any or all of the foregoing.

                                   Exhibit A
<PAGE>

                                    EXHIBIT B

                                   [reserved]

                                    EXHIBIT C

                                   [reserved]

                                    EXHIBIT D

                                   [reserved]

<PAGE>

                                    EXHIBIT E

                             COMPLIANCE CERTIFICATE

TO: SILICON VALLEY BANK                                          Date: _________

FROM: ________________

     The undersigned authorized officer of each of ENDOCARE, INC., a Delaware
corporation ("Endocare"), and TIMM MEDICAL TECHNOLOGIES, INC., a Delaware
corporation ("TIMM") (individually and collectively, and jointly and severally,
"Borrower"), certifies that under the terms and conditions of the Loan and
Security Agreement between Borrower and Bank (as amended, restated,
supplemented, or otherwise modified from time to time, the "Agreement"), (1)
Borrower is in complete compliance for the period ending _______________ with
all required covenants except as noted below, (2) there are no Events of
Default, (3) all representations and warranties in the Agreement are true and
correct in all material respects on this date except as noted below; provided,
however, that such materiality qualifier shall not be applicable to any
representations and warranties that already are qualified or modified by
materiality in the text thereof; and provided, further that those
representations and warranties expressly referring to a specific date shall be
true, accurate and complete in all material respects as of such date, (4)
Borrower, and each of its Subsidiaries, has timely filed all required tax
returns and reports, and Borrower has timely paid all material foreign, federal,
state and local taxes, assessments, deposits and contributions owed by Borrower
except as otherwise permitted pursuant to the terms of Section 5.9 of the
Agreement, (5) at the end of the month most recently ended there were no held
checks, and (6) no Liens have been levied or claims made against Borrower or any
of its Subsidiaries relating to unpaid employee payroll or benefits of which
Borrower has not previously provided written notification to Bank. Attached are
the required documents supporting the certification. The undersigned certifies
that these are prepared in accordance with generally GAAP consistently applied
from one period to the next except as explained in an accompanying letter or
footnotes. The undersigned acknowledges that no borrowings may be requested at
any time or date of determination that Borrower is not in compliance with any of
the terms of the Agreement, and that compliance is determined not just at the
date this certificate is delivered. Capitalized terms used but not otherwise
defined herein shall have the meanings given them in the Agreement.

PLEASE INDICATE COMPLIANCE STATUS BY CIRCLING YES/NO UNDER "COMPLIES" COLUMN.

<TABLE>
<CAPTION>
          REPORTING COVENANT                      REQUIRED            COMPLIES
          ------------------                      --------            --------
<S>                                      <C>                          <C>
Monthly financial statements with        Monthly within 30 days        Yes No
Compliance Certificate

10-Q, 10-K and 8-K (and Compliance       Within 5 days after filing    Yes No
Certificate with each 10-Q and 10K)      with SEC (subject to
                                         Section 6.2(b) of the
                                         Agreement)

Borrowing Base Certificate/Transaction   Monthly within 15 days        Yes No
Report, A/R & A/P Agings, Inventory
Report, Deferred Revenue Report
</TABLE>

The following Intellectual Property was registered after the Effective Date (if
no registrations, state "None")

--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
        FINANCIAL COVENANT            REQUIRED    ACTUAL    COMPLIES
        ------------------            --------    ------    --------
<S>                                  <C>         <C>        <C>
Maintain on a MONTHLY Basis:
Minimum Tangible Net Worth            $_______   $_______    Yes No
</TABLE>

<TABLE>
<CAPTION>
PHASE I STATUS AND PHASE II STATUS    REQUIRED    ACTUAL    COMPLIES
----------------------------------    --------    ------    --------
<S>                                  <C>         <C>        <C>
Maintain on a MONTHLY Basis:
Minimum Quick Ratio                  1.00:1.00   __:1.00     Yes No
</TABLE>

                                       1

<PAGE>

     The following financial covenant analysis and information set forth in
Schedule 1 attached hereto are true and accurate as of the date of this
Certificate.

     The following are the exceptions with respect to the certification above:
(If no exceptions exist, state "No exceptions to note.")

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

ENDOCARE, INC., a Delaware corporation   BANK USE ONLY

                                         Received by:
                                                      --------------------------
                                                      AUTHORIZED SIGNER

By:
    ----------------------------------   Date:
Name:                                          ---------------------------------
      --------------------------------
Title:                                   Verified:
       -------------------------------             -----------------------------
                                                   AUTHORIZED SIGNER

TIMM MEDICAL TECHNOLOGIES, INC., a       Date:
Delaware corporation                           ---------------------------------

                                         Compliance Status: Yes No

By:
    ----------------------------------
Name:
      --------------------------------
Title:
       -------------------------------

                                       2

<PAGE>

                      SCHEDULE 1 TO COMPLIANCE CERTIFICATE

         FINANCIAL COVENANTS OF BORROWER/PHASE I & PHASE II CALCULATIONS

Dated: ____________________

I.   TANGIBLE NET WORTH (Section 6.9(a))

Required: $____

Actual:

A. Aggregate value of total consolidated assets of Endocare and its
   Subsidiaries                                                         $_______

B. Aggregate value of consolidated goodwill of Endocare and its
   Subsidiaries                                                         $_______

C. Aggregate value of consolidated intangible assets of Endocare and
   its Subsidiaries                                                     $_______

D. Aggregate value of any reserves not already deducted from assets     $_______

E. Aggregate value of consolidated liabilities of Endocare and its
   Subsidiaries (including all Indebtedness)
   (but excluding Subordinated Debt)                                    $_______

F. Tangible Net Worth (line A minus line B minus line C minus line
   D minus line E)                                                      $_______

Is line F. equal to or greater than $_____?

   _________ No, not in compliance                  _________ Yes, in compliance

                                       3

<PAGE>

II.  QUICK RATIO (Section 1A)

Required "Quick Ratio Threshhold": 1.00:1.00

Actual:

A. Aggregate value of the unrestricted cash and cash equivalents of
   Endocare and its Subsidiaries, on a consolidated basis              $ _______

B. Aggregate value of the net billed accounts receivable of Endocare
   and its Subsidiaries, on a consolidated basis                       $ _______

C. Aggregate value of the Investments with maturities of fewer than 12
   months of Endocare and it Subsidiaries, on a consolidated basis     $ _______

D. Quick Assets (the sum of lines A through C)                         $ _______

E. Current Liabilities, i.e., the portion of Total Liabilities
   (including all Indebtedness) of Endocare and its Subsidiaries, on
   a consolidated basis that matures within one (1) year               $ _______
   [remember that Total Liabilities is defined to exclude
   Subordinated Debt.]

F. Quick Ratio (line D divided by line E)                              $ _______

Is line F equal to or greater than 1.00:1:00?

     ________ No                                               ________ Yes

                                       4<PAGE>

                                                                   Exhibit 10.29

                           COMMERCIALIZATION AGREEMENT

     THIS COMMERCIALIZATION AGREEMENT (this "Agreement") is executed and
delivered as of November 8, 2005 (the "Effective Date"), by and between
Endocare, Inc., a Delaware corporation ("Endocare"), and CryoDynamics, LLC, a
Michigan limited liability company ("CryoDynamics"). Each of Endocare and
CryoDynamics is referred to herein as a "Party," and, collectively, the
"Parties."

                                    RECITALS

     WHEREAS, Endocare and MediPhysics, LLC, a Michigan limited liability
company ("MediPhysics"), executed and delivered that certain Design and
Development Contract, dated as of March 28, 2005 (the "Development Contract");

     WHEREAS, following the execution and delivery of the Development Contract
MediPhysics assigned all of its rights and obligations under the Development
Contract (and all of its other assets and liabilities) to CryoDynamics;

     WHEREAS, the Development Contract set forth the intention of the Parties to
develop and commercialize medical applications based upon both Parties patents
and know how;

     WHEREAS, the parties desire to supersede and replace the Development
Contract with this Agreement; and

     WHEREAS, this Agreement sets forth the terms and conditions regarding the
commercialization of existing inventions that arose out of the Development
Contract and future inventions arising out of this Agreement.

     NOW, THEREFORE, in consideration of the foregoing and of the mutual
promises contained herein, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereby agree as follows:

                                    AGREEMENT

1. DEFINITIONS. The following capitalized terms shall have the meanings as
defined below:

     1.1 "AFFILIATE" shall mean any Person (whether now existing or hereafter
arising) which, directly or indirectly, controls, is controlled by or is under
common control with another Person (whether now existing or hereafter arising);
for purposes of the foregoing, "control," "controlled by" and "under common
control with" with respect to any Person shall mean the possession, directly or
indirectly, of the power (i) to vote 10% or more of the securities having
ordinary voting power for the election of directors of such Person, or (ii) to
direct or cause the direction of the management and policies of such Person,
whether through the ownership of voting securities or by contract or otherwise.

     1.2 "CONFIDENTIAL INFORMATION" shall mean any and all information and
materials disclosed by one Party to another Party pursuant to this Agreement
(whether in writing or in oral,

<PAGE>

graphic, electronic or any other form) that are marked or described as,
identified in writing as, or provided under circumstances indicating that such
information and materials are confidential or proprietary. Information or
materials shall not be considered Confidential Information to the extent such
information or materials can be shown to have been: (a) available to the public
prior to the date of disclosure to the other party or to have become available
to the public; (b) rightfully in possession of the other party prior to the date
of disclosure and not otherwise restricted as to disclosure; (c) independently
developed by the other Party without use of or reference to the Confidential
Information of the other Party; or (d) disclosed to other Party without
restriction by a third party who had a right to disclose and was not otherwise
under an obligation of confidence.

     1.3 "COPYRIGHTS" shall mean all copyrights, including, without limitation,
in and to works of authorship and all other rights corresponding thereto
throughout the world, whether published or unpublished, including, without
limitation, rights to prepare, reproduce, perform, display and distribute
copyrighted works and copies, compilations and derivative works thereof.

     1.4 "DEVELOPMENT INVENTION" shall have the meaning set forth in Section 3.1
below.

     1.5 "ENDOCARE EXISTING PRODUCT" any product that is in Endocare's existing
product line that is sold by Endocare, its (sub)licensees (other than
CryoDynamics) or their respective Affiliates and that incorporates, uses or
includes an Endocare Invention.

     1.6 "ENDOCARE INVENTION" shall have the meaning set forth in Section 3.2
below.

     1.7 "INTELLECTUAL PROPERTY RIGHTS" shall mean any and all rights in and to
intellectual property and intangible industrial property rights, including,
without limitation: (i) Patents, Trade Secrets, Copyrights and Trademarks; and
(ii) any rights similar, corresponding or equivalent to any of the foregoing
anywhere in the world.

     1.8 "NET CRYODYNAMICS REVENUES" shall mean all amounts received by
CryoDynamics from the (sub)licensing or commercialization of the Development
Inventions that were the subject of a notification letter approved by Endocare
pursuant to Section 4.3, but excluding amounts received to reimburse
CryoDynamics' cost to perform research, development or similar services, in
reimbursement of patent or other out-of-pocket expenses, or in consideration for
the purchase of any securities of CryoDynamics (at a price up to one hundred
percent (100%) of the then fair market value of such securities).

     1.9 "NET ENDOCARE REVENUES" shall mean:

          (A) all amounts received by Endocare from the (sub)licensing of
Development Inventions (other than royalties received from CryoDynamics for Net
CryoDynamics Revenues), but excluding amounts received to reimburse Endocare's
cost to perform research, development or similar services, in reimbursement of
patent or other out-of-pocket expenses, or in consideration for the purchase of
any securities of Endocare (at a price up to one hundred percent (100%) of the
then fair market value of such securities).

          (B) Five percent (5%) of all amounts received by Endocare for the
sales of products sold by Endocare that are solely based upon a Development
Invention less (i) credits,

                                       2

<PAGE>

allowances, discounts and rebates to, and chargebacks from the account of, such
customers for damaged and returned products; (ii) freight and insurance costs
incurred in transporting such products to customers; (iii) cash, quantity and
trade discounts, rebates and other price reductions for such products given to
such customers under price reduction programs that are consistent with industry
practices; (iv) sales, use, value-added and other direct taxes incurred on the
sale of products to customers; and (v) customs duties, surcharges and other
governmental charges incurred in exporting or importing such products to
customers. To the extent Endocare incorporates a Development Invention into an
Endocare Existing Product, CryoDynamics will be compensated based upon Section
5.2.

     1.10 "NITROGEN SYSTEM AND APPARATUS" shall mean the nitrogen system that is
developed, modified and/or improved by CryoDynamics pursuant to the Development
Contract and/or this Agreement.

     1.11 "PATENTS" shall mean all United States and foreign patents and utility
models and applications therefore and all reissues, divisions, re-examinations,
renewals, extensions, provisionals, continuations and continuations-in-part
thereof, and equivalent or similar rights anywhere in the world in inventions
and discoveries.

     1.12 "PERSON" shall include any individual and any corporation, limited
liability company, limited or general partnership or other entity.

     1.13 "PRE-EXISTING TECHNOLOGY" shall mean all technology in or to the
Nitrogen System and Apparatus (other than Development Inventions) that are
reasonably necessary for Endocare to use, access or incorporate in order to
exercise its rights under this Agreement with respect to the research,
development, making, using, offering for sale or importing of Endocare Existing
Products or Development Inventions.

     1.14 "TRADEMARKS" shall mean any and all trademarks, service marks, logos,
trade names, corporate names, Internet domain names and addresses and
general-use e-mail addresses, and all goodwill associated therewith throughout
the world.

     1.15 "TRADE SECRETS" shall mean all trade secrets under applicable law and
other rights in know-how and confidential or proprietary information,
processing, manufacturing or marketing information, including, without
limitation, new developments, inventions, processes, ideas or other proprietary
information that provide a Person with advantages over competitors who do not
know or use such information and documentation thereof (including, without
limitation, related papers, blueprints, drawings, chemical compositions,
formulae, diaries, notebooks, specifications, designs, methods of manufacture
and data processing software, compilations of information) and all claims and
rights related thereto.

2. PROJECTS.

     2.1 NITROGEN SYSTEM AND APPARATUS. CryoDynamics will design and develop a
Nitrogen System and Apparatus, using CryoDynamics' technology. CryoDynamics will
provide Endocare with one or more prototypes of the Nitrogen System and
Apparatus and documentation and information sufficient to enable Endocare to
evaluate and perform developmental testing on the Nitrogen System and Apparatus.

                                       3

<PAGE>

          (A) DELIVERY. CryoDynamics will use its best efforts to deliver the
Nitrogen System and Apparatus to Endocare. CryoDynamics will deliver the
Nitrogen System and Apparatus to Endocare at Endocare's Irvine, California
facility.

          (B) DEVELOPMENT TESTING. Endocare will have the right to evaluate and
test the Nitrogen System and Apparatus. CryoDynamics will provide technical
support to Endocare during Endocare's evaluation and testing of the Nitrogen
System and Apparatus.

     2.2 DEVELOPMENT OF ENHANCEMENTS TO ENDOCARE EXISTING PRODUCTS OR
TECHNOLOGY. CryoDynamics will provide developmental assistance on the Endocare
Existing Products. CryoDynamics will apply its Intellectual Property, as was set
forth on Exhibit B to the Development Contract, to accomplish these enhancements
of the Endocare product line.

3. INVENTIONS. The parties acknowledge and agree that:

     3.1 DEVELOPMENT INVENTIONS. Except as set forth in Section 3.2, below, the
Parties jointly own all right, title and interest in and to all inventions,
discoveries, compositions, enhancements, technologies, data or information
(whether or not patentable) made or conceived by CryoDynamics in the performance
of, and during the term of, the Development Contract or this Agreement
(collectively, the "DEVELOPMENT INVENTIONS").

     3.2 ENDOCARE INVENTIONS. Endocare solely owns all right, title and interest
in and to all inventions, discoveries, compositions, enhancements, technologies,
data or information (whether or not patentable) in each case that are related to
Endocare's current product line and that are made or conceived by CryoDynamics
in the performance of, and during the term of, the Development Contract or this
Agreement (collectively, the "ENDOCARE INVENTIONS"). CryoDynamics hereby sells,
assigns and transfers to Endocare all of CryoDynamics' right, title and interest
therein and thereto.

     3.3 ONGOING RESEARCH AND DEVELOPMENT. CryoDynamics and Endocare desire to
conduct further research and development of the Nitrogen System and Apparatus to
demonstrate that the technology can be used as the basis for commercial products
in the medical field to provide clinical benefits to patients. To assist
CryoDynamics in its continued research and development efforts, Endocare will
advance CryoDynamics $42,500 per month beginning October 1, 2005. This monthly
advance by Endocare will continue until such time as either Endocare or
CryoDynamics enters into a license agreement based upon the Nitrogen Systems and
Apparatus with an independent third party that results in CryoDynamics receiving
an amount sufficient to repay any funds advanced by Endocare and fund their
monthly operating expenses of $42,500.

4. LICENSE GRANTS.

     4.1 TO ENDOCARE. Subject to the terms and conditions of this Agreement,
CryoDynamics hereby grants to Endocare under all of CryoDynamics' Intellectual
Property Rights an exclusive, worldwide license (with the right to sublicense)
to research, develop, make, use, sell, offer for sale, import or practice the
Development Inventions and Pre-Existing Technology in all medical fields of use.

                                       4

<PAGE>

     4.2 TO CRYODYNAMICS. Subject to the terms and conditions of this Agreement,
with respect to those Development Inventions that were the subject of a
notification letter approved by Endocare pursuant to Section 4.3, Endocare
hereby grants to CryoDynamics under all of Endocare's Intellectual Property
Rights an exclusive, worldwide license (with the right to sublicense) to
research, develop, make, use, sell, offer for sale, import or practice such
Development Invention in the field of use specified in such notification letter.

     4.3 OPPORTUNITIES. During the term of this Agreement, if CryoDynamics
provides to Endocare a notification letter that sets forth a proposed business
opportunity involving a Development Invention in a field of use and Endocare
notifies CryoDynamics in writing that Endocare does not desire to commercialize
such opportunity, then (a) CryoDynamics shall have the right to commercialize
such opportunity, subject to the payment of royalties set forth below, and (b)
Endocare shall grant to CryoDynamics the license set forth in Section 4.2 above
with respect to the applicable Development Invention and field of use.
Notwithstanding the foregoing, CryoDynamics acknowledges and agrees that
Endocare shall not be obligated to participate, carry on, authorize, assist or
finance CryoDynamics in any way with respect to any such opportunity that
Endocare has notified CryoDynamics that Endocare does not desire to
commercialize such opportunity. In those situations in which Endocare provides
written notification to CryoDynamics that it does not desire to commercialize a
particular business opportunity, CryoDynamics will pay Endocare twenty-five
percent (25%) of all amounts received by CryoDynamics from the (sub)licensing
related to the specific opportunity. Furthermore, should the situation arise in
which CryoDynamics deems it to be in their best interest to commercialize a
particular opportunity that Endocare has declined to commercialize, the parties
agree that CryoDynamics will pay Endocare twenty-five percent (25%) of five
percent (5%) of all amounts received by CryoDynamics on a basis consistent with
section 1.9(b).

5. FINANCIAL CONSIDERATIONS.

     5.1 DEVELOPMENT INVENTION ROYALTIES. The Parties agree that all royalties
or license fees related to one parties commercialization of a Development
Invention will be handled on the following basis:

          (A) First, all amounts paid/advanced by either Party (including
without limitation, any and all funds advanced to CryoDynamics by Endocare for
development work, patent legal costs and other such expenses of CryoDynamics)
will be reimbursed to such Party from any revenues received by a Party for the
licensing or commercialization of a Development Invention before calculating the
Net CryoDynamics Revenues or Net Endocare Revenues (as applicable).

          (B) Second, an amount will be paid to each of the Parties, from any
revenues received by a Party for the licensing or commercialization of a
Development Invention before calculating the Net CryoDynamics Revenues or Net
Endocare Revenues (as applicable), to reimburse each of them at a reasonable,
mutually agreed upon rate for any services required under this Agreement that
has not been advanced/paid for separately in the agreement.

          (C) Finally, Endocare shall pay to CryoDynamics twenty-five percent
(25%) of remaining Net Endocare Revenues and CryoDynamics shall pay to Endocare
seventy-five

                                       5

<PAGE>

percent (75%) of remaining Net CryoDynamics Revenues, subject to Section 4.3,
such that the seventy-five percent (75%) refers only to situations in which
CryoDynamics has taken the lead on licensing agreements in a field of use
specified as an area of interest by Endocare.

     5.2 ENDOCARE EXISTING PRODUCTS. For any Endocare Existing Products that a
Development Invention is incorporated by Endocare, Endocare will pay to
CryoDynamics five percent (5%) of (i) the net reduction in the total costs of
the materials used to manufacture the product associated with the Develop
Invention, less any increase in labor costs, if any, less (ii) reimbursement to
Endocare by CryoDynamics for any payments made by Endocare to CryoDynamics
during the development of the Development Invention, if any, that has not been
separately reimbursed pursuant to Section 5.1 above ("Net Endocare Existing
Products Revenue"). Should the situation arise that Endocare wants to implement
a Development Invention, but there is no cost savings, the Parties will mutually
agree upon an appropriate payment to CryoDynamics.

     5.3 PAYMENT REPORTS.

          (A) Within sixty (60) days after the end of each calendar quarter
during the term of this Agreement, and within sixty (60) days following the
expiration or termination of this Agreement, Endocare shall furnish to
CryoDynamics a written report showing in reasonably specific detail all Net
Endocare Revenues and Net Endocare Existing Product Revenues and the calculation
of the royalties, if any, that shall have accrued based upon such amounts.

          (B) Within sixty (60) days after the end of each calendar quarter
during the term of this Agreement, and within sixty (60) days following the
expiration or termination of this Agreement, CryoDynamics shall furnish to
Endocare a written report showing in reasonably specific detail all Net
CryoDynamics Revenues and the calculation of the royalties, if any, that shall
have accrued based upon such amounts.

          (C) With respect to amounts received in a currency other than United
States dollars, all such amounts shall be expressed both in the currency in
which such amounts were received and in the United States dollar equivalent. The
United States dollar equivalent shall be calculated using the average of the
exchange rate (local currency per US$1) published in The Wall Street Journal,
Western Edition, under the heading "Currency Trading" on the last business day
of each month during the applicable calendar quarter.

          (D) Each party shall keep complete and accurate records in sufficient
detail to enable the amounts payable hereunder to be determined.

          5.4 AUDITS.

          (A) Upon the written request of a party (the "Payee") and not more
than once in each calendar year, the other party (the "Payor") shall permit an
independent certified public accounting firm of nationally recognized standing,
selected by the Payee and reasonably acceptable to the Payor, at the Payee's
expense, to have access during normal business hours to such of the records of
the Payor as may be reasonably necessary to verify the accuracy of the payment
reports hereunder for the eight (8) calendar quarters immediately prior to the
date of

                                       6

<PAGE>

such request (other than records for which the Payee has already conducted an
audit under this Section).

          (B) If such accounting firm concludes that additional amounts were
owed during the audited period, the Payor shall pay such additional amounts
within thirty (30) days of the date the Payee delivers to the Payor such
accounting firm's written report so concluding. The fees charged by such
accounting firm shall be paid by the Payee; provided, however, if the audit
discloses that the royalties payable by the Payor for such period are more than
one hundred ten percent (110%) of the royalties actually paid for such period,
then the Payor shall pay the reasonable fees and expenses charged by such
accounting firm.

          (C) The Payee shall cause its accounting firm to retain all financial
information subject to review under this Section 5.2 in strict confidence;
provided, however, that the Payor shall have the right to require that such
accounting firm, prior to conducting such audit, enter into an appropriate
non-disclosure agreement with the Payor regarding such financial information.
The accounting firm shall disclose to the Payee only whether the reports are
correct or not and the amount of any discrepancy. No other information shall be
shared. The Payee shall treat all such financial information as Payor's
Confidential Information.

     5.5 PAYMENT TERMS. All amounts shown to have accrued by each payment report
provided for under Section 5.2 above shall be payable on the date such payment
report is due. Payment of amounts in whole or in part may be made in advance of
such due date.

     5.6 PAYMENT METHOD. All payments by the Payor to the Payee under this
Agreement shall be paid in United States dollars and all such payments shall be
originated from a United States bank located in the United States and made by
bank wire transfer in immediately available funds to such account as the Payee
shall designate before such payment is due.

     5.7 EXCHANGE CONTROL. If at any time legal restrictions prevent the prompt
remittance of part or all royalties with respect to any country where amounts
are received by the Payor, the Payor shall have the right, at its option, to
make such payments by depositing the amount thereof in local currency to the
Payee's account in a bank or other depository in such country. If the royalty
rate specified in this Agreement should exceed the permissible rate established
in any country, the royalty rate for sales in such country shall be adjusted to
the highest legally permissible or government-approved rate.

     5.8 WITHHOLDING TAXES. The Payor shall be entitled to deduct the amount of
any withholding taxes, value-added taxes or other taxes, levies or charges with
respect to such amounts, other than United States taxes, payable by the Payor,
or any taxes required to be withheld by the Payor, to the extent the Payor pays
to the appropriate governmental authority on behalf of the Payee such taxes,
levies or charges. The Payor shall use reasonable efforts to minimize any such
taxes, levies or charges required to be withheld on behalf of the Payee by the
Payor. The Payor promptly shall deliver to the Payee proof of payment of all
such taxes, levies and other charges, together with copies of all communications
from or with such governmental authority with respect thereto.

                                       7

<PAGE>

6. REPRESENTATIONS, WARRANTIES AND COVENANTS OF CRYODYNAMICS; INDEMNIFICATION.

     6.1 PRODUCTS AND SERVICES. CryoDynamics represents, warrants and covenants
that: (a) CryoDynamics shall comply with all applicable laws and regulations
with respect to its performance under this Agreement; (b) the Nitrogen System
and Apparatus delivered to Endocare hereunder shall be satisfactory for the
purposes of developmental testing; and (c) any services performed hereunder
shall be performed in a professional and competent manner.

     6.2 INTELLECTUAL PROPERTY RIGHTS OF OTHERS. In connection with its
performance of this Agreement, neither party infringe or otherwise violate any
third party's intellectual property rights, nor shall either Party and shall not
directly or indirectly cause the other to do so. The indemnification provisions
contained in the following section apply to these obligations.

     6.3 INDEMNIFICATION.

          (A) CryoDynamics shall indemnify, defend and hold harmless, Endocare
and its Affiliates, and their respective officers, directors, employees,
consultants, customers, successors and assigns, from and against any and all
claims of third parties for losses, liabilities, costs, damages, claims, fines,
penalties and expenses (including, without limitation, costs of defense or
settlement and reasonable attorneys', consultants' and experts' fees) that arise
out of or result from: (a) injuries or death to persons or damage to property,
in any way arising out of or caused or alleged to have been caused by the work
or services performed by, or the Nitrogen System and Apparatus provided by,
CryoDynamics before the date of delivery of the Nitrogen System and Apparatus to
Endocare; (b) assertions under workers' compensation or similar acts made by
persons employed by or otherwise associated with CryoDynamics; (c) any breach of
any representation, warranty or covenant by CryoDynamics or failure of
CryoDynamics to perform any of its obligations under this Agreement; or (d)
violation of any applicable law or regulation in any way arising out of or
caused or alleged to have been caused by CryoDynamics' work or services under
this Contract or by the Nitrogen System and Apparatus provided by CryoDynamics.

          (B) Endocare shall indemnify, defend and hold harmless, CryoDynamics
and its Affiliates, and their respective officers, directors, employees,
consultants, customers, successors and assigns, from and against any and all
claims of third parties for losses, liabilities, costs, damages, claims, fines,
penalties and expenses (including, without limitation, costs of defense or
settlement and reasonable attorneys', consultants' and experts' fees) that arise
out of or result from: (a) injuries or death to persons or damage to property,
in any way arising out of or caused or alleged to have been caused by the work
or services performed by, or the Nitrogen System and Apparatus provided by,
CryoDynamics after the date of delivery of the Nitrogen System and Apparatus to
Endocare; (b) assertions under workers' compensation or similar acts made by
persons employed by or otherwise associated with Endocare; (c) any breach of any
representation, warranty or covenant by Endocare or failure of Endocare to
perform any of its obligations under this Agreement; or (d) violation of any
applicable law or regulation in any way arising out of or caused or alleged to
have been caused by Endocare's developmental testing of the Nitrogen System and
Apparatus provided by CryoDynamics.

                                       8

<PAGE>

7. RIGHT OF FIRST REFUSAL. During the term of this Agreement, should
CryoDynamics intend to accept an offer from any potential buyer for the sale of
all or part of CryoDynamics' business (whether by asset sale, merger,
reorganization, change of control, operation of law or otherwise) (a "Third
Party Offer"), CryoDynamics shall first notify Endocare in writing and provide
to Endocare a written copy of the terms and conditions of such Third Party
Offer. For a period of sixty (60) days following the receipt of such notice and
a copy of such Third Party Offer (the "Review Period"), Endocare shall have the
right to acquire CryoDynamics on substantially the same terms and conditions set
forth in such Third Party Offer. If, during such sixty (60) days, the applicable
third party alters the terms of the applicable Third Party Offer in a negative
manner (with respect to CryoDynamics), then CryoDynamics shall provide Endocare
with a written copy of such revised Third Party Offer, and (i) Endocare shall
have the right to acquire CryoDynamics on substantially the same terms and
conditions set forth in such revised Third Party Offer, and (ii) the Review
Period for such revised Third Party Offer shall be extended by an additional
thirty (30) days.

8. TERM AND TERMINATION.

     8.1 TERM. The term of this Agreement shall commence on the Effective Date
and shall continue until the later of (a) December 31, 2015, and (b) the parties
obligations to pay royalties pursuant to Section 5 above, or until terminated
pursuant to Section 8.2.

     8.2 TERMINATION FOR BREACH, ETC. Either Party may terminate this Agreement
in the event that: (a) the other Party breaches any provision of this Agreement
and such breach continues for a period of thirty (30) days following the receipt
by the breaching Party of written notice of such breach; or (b) the other Party
becomes insolvent, is adjudicated bankrupt, voluntarily or involuntarily files a
petition for bankruptcy, makes an assignment for the benefit of creditors, seeks
any other similar relief under any bankruptcy law or related statues or
otherwise becomes financially incapable of performing its obligations in
accordance with the terms of this Agreement, and such judgment, assignment or
incapacity is not revoked within sixty (60) days.

9. CONFIDENTIALITY.

     9.1 RESTRICTIONS ON DISCLOSURE AND USE OF CONFIDENTIAL INFORMATION. Neither
Party shall use the Confidential Information of the other Party except for the
purpose of performing its obligations under this Agreement. Each party shall
maintain the Confidential Information of the other Party with at least the same
degree of care it uses to protect its own confidential information of a similar
nature or sensitivity, but no less than reasonable care under the circumstances.
Unless a Party grants specific, written, advance permission to do so, the other
Party shall not disclose any Confidential Information to any third party except
as provided in Section 9.2. Each Party shall limit access to the Confidential
Information of other Party to their employees and independent contractors who
have a need to know such information in order to perform the Party's obligations
and exercise its rights under this Agreement and who are bound by
confidentiality and non-use obligations to the Party at least equivalent to the
Party's obligations to the other Party under this Agreement.

                                       9

<PAGE>

     9.2 EXCEPTIONS. Either Party may disclose Confidential Information of the
other Party to the extent required by Law or order of a court of competent
jurisdiction, provided that, in such event, the disclosing party shall provide
the other party prompt, advance written notice of such requirement.

     9.3 RETURN OF CONFIDENTIAL INFORMATION. Upon any termination of this
Agreement both Parties shall return or destroy all Confidential Information of
Discloser and any copies thereof.

     9.4 NO PUBLIC STATEMENTS. CryoDynamics will not issue any press release or
otherwise make any public statements with respect to the transactions
contemplated by this Agreement without the prior written consent of Endocare,
except as may be required by applicable law.

10. MISCELLANEOUS.

     10.1 ASSIGNMENT. Neither Party shall assign, transfer, delegate or
otherwise dispose of, any rights or obligations under this Agreement without the
prior written consent of the other Party; provided, however, that the foregoing
limitation shall not apply to any acquisition involving a Party (whether
structured as a merger or sale of stock or assets) or to an assignment by
CryoDynamics to another limited liability company composed of the same members
as CryoDynamics. Except as provided herein, any purported assignment, transfer,
delegation or other disposition by either Party shall be null and void. Subject
to the foregoing, this Agreement shall be binding upon and shall inure to the
benefit of the Parties and their respective successors and permitted assigns.

     10.2 GOVERNING LAW; JURISDICTION AND VENUE. This Agreement is to be
construed in accordance with and governed by the laws of the State of California
without giving effect to any choice of law rule that would cause the application
of the laws of any jurisdiction other than the laws of the State of California
to the rights and duties of the Parties. The exclusive jurisdiction and venue
for any dispute arising out of this Agreement shall be (1) in the federal or
state courts located in Irvine, California, if CryoDynamics institutes the
action, or (2) in the federal or state courts located in Detroit, Michigan, if
Endocare institutes the action.

     10.3 FURTHER ASSURANCES. At any time or from time to time on and after the
date of this Agreement, CryoDynamics shall, at the request of Endocare, promptly
(a) deliver to Endocare such records, data or other documents consistent with
the provisions of this Agreement, (b) execute and deliver or cause to be
delivered all such assignments, consents, documents or further instruments of
transfer or license, and (c) take or cause to be taken all such other actions as
Endocare may reasonably deem necessary or desirable in order for Endocare to
obtain the full benefits of this Agreement and the transactions contemplated
hereby.

     10.4 NON-WAIVER. Failure by any Party to insist upon strict performance of
any of the terms and conditions hereof, or delay in exercising any rights or
remedies provided herein, shall not release the other Party from any of the
obligations of this Agreement and shall not be deemed a waiver of any rights of
any Party to insist upon strict performance thereof.

                                       10

<PAGE>

     10.5 ATTORNEYS' FEES. In the event either Party brings legal action to
enforce any provision herein, the prevailing Party shall be entitled to collect
from the losing Party reasonable attorneys' fees and costs incurred.

     10.6 ENTIRE AGREEMENT AND MODIFICATION. No other agreement or
understanding, including the Development Contract which is hereby expressly
superseded and replaced, in any way modifying these terms and conditions, either
before or after the execution hereof, shall be binding upon either Party unless
in writing and signed by all of the Parties. This Agreement constitutes the
entire Agreement between the Parties. In the event of any conflict between the
terms and conditions of this Agreement and those of any purchase order or any
other document, the terms and conditions of this Agreement shall control.

     10.7 STATUS OF THE PARTIES. Each Party hereby represents and warrants that
it is engaged in an independent business and shall perform its obligations under
this Agreement as an independent contractor and not as an agent or employee of
or a joint venturer of the other Party; that the Persons performing the services
hereunder on behalf of such Party are not agents or employees of the other
Party; that it has and hereby retains, except as set forth herein, the right to
exercise full control with respect to the means of its performance hereunder and
full control over the employment, direction, compensation and discharge of all
employees, agents and subcontractors assisting in such performance; that it
shall be solely responsible for all matters relating to payment of such
employees, including compliance with worker's compensation, unemployment and
disability insurance, social security withholding, and all such matters; and
that it shall be responsible for its acts and the acts of all agents, employees
and contractors employed by it during its performance under this Agreement.

     10.8 SEVERABILITY. If any one or more of the provisions contained in this
Agreement shall, for any reason, be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect
any other provision hereof, and this Agreement shall be construed as if such
invalid, illegal or unenforceable provision had never been contained herein.

     10.9 NOTICE. All notices required hereunder shall be in writing and shall
be sent by a recognized courier service (e.g., UPS, DHL, Federal Express) or
certified mail, with all postage or delivery charges prepaid, and shall be
addressed to the Parties at their addresses set forth on the signature page of
this Agreement or to such other address (es) as may be furnished by written
notice in the manner set forth herein. Notice is effective upon receipt.

     10.10 HEADINGS. The headings of the Sections in this Agreement are for
convenience only and shall not be deemed to affect, qualify, simplify, add to or
subtract from the contents of the clauses that they reference.

     10.11 COUNTERPARTS. This Agreement may be executed in counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

     IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed by its duly authorized representative.

                                       11

<PAGE>

ENDOCARE, INC.                          CRYODYNAMICS, LLC

By: /s/ William J. Nydam                By: /s/ Peter J. Littrup, M.D.
    ---------------------------------       ------------------------------------
Name: William Nydam                     Name: Peter J. Littrup, M.D.
Title: President/COO                    Title: Managing Partner

Address for Notices:                    Address for Notices:

201 Technology Drive                    951 Timberlake
Irvine, California  92618               Bloomfield Hills, MI 48302
Attention: Jay Eum                      Attention: Peter J. Littrup

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]